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ABSTRACT OF THE DISSERTATION
THE IMMUNOSUPPRESSIVE ROLE OF EDN3/EDNRB SIGNALING IN THE
MELANOMA MICROENVIRONMENT
by
Juliano Freitas
Florida International University, 2019
Miami, Florida
Professor Lidia Kos, Major Professor
Endothelins are cytokines ubiquitously expressed in the microenvironment of
several tumors. In melanoma is not clear whether stromal cells respond to the
endothelin present in the microenvironment. To address this question, I generated
tumors derived from different murine melanoma cell lines (B16F10, YUMM1.7,
YUMMER1.7) in a transgenic mouse that overexpresses endothelin 3 (Edn3) by
keratinocytes in the skin (K5-Edn3). Tumors from all the cell lines grew larger and
were more aggressive when Edn3 was overexpressed in the skin. In tumors
derived from YUMM1.7-GFP cells, very few tumorigenic cells expressed the Edn3
receptor, Endothelin receptor b (Ednrb) suggesting an environmental role for
endothelin signaling in melanoma microenvironment. The present study showed
for the first time that Ednrb is expressed in several cell populations inside
melanoma microenvironment. The clinical relevance of the finding was validated
using publicly available RNA-seq data from melanoma patients. Regulatory T cells
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(Tregs) was the only population that was numerically different when K5-Edn3
tumors were compared to wild-type tumors suggesting that Edn3 promotes Treg
enrichment in melanoma microenvironment.
The present study supports the notion that endothelin promotes the formation
of an immunosuppressive milieu in melanoma facilitating escape from tumor
immunity. Endothelin was required for immune escape of highly immunogenic
melanoma cells YUMMER1.7. The immunosuppressive features of Tregs were
enhanced in presence of Edn3. The master regulator of Tregs’ suppressive
functions, FOXP3, was remarkably upregulated in K5-Edn3 tumors as well as
immunosuppressive cytokines TGF-β and IL-10. Overexpression of Edn3 in the
tumor microenvironment prevented the expansion of CTLs possibly via GZBmediated cytolysis. Expression of chemokines and inflammatory cytokines were
downregulated in K5-Edn3 tumors. Cytokines that elicit anti-tumor immunity,
exhibited reduced levels in K5-Edn3 tumors. The YUMM1.7-GFP tumors exposed
to high levels of Edn3 were sensitive to immune checkpoint inhibitor (anti-CTLA-4)
as well as to Ednrb blockage (BQ-788). The response to BQ-788 was more
pronounced suggesting that EDNRB targeting might be an alternative therapeutic
strategy for melanoma patients that are under immunotherapy regimen.
In conclusion, the present study indicates that Edn3/Ednrb signaling has an
important

role

in

the

melanoma

microenvironment

where

immunosuppression resulting in escape from tumor immunity.
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CHAPTER
1. Introduction
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1.1.

Melanoma

Melanoma is a highly metastatic cancer and the number of new cases of
melanoma in the United States has been increasing for the last 30 years.
According to the American Cancer Society 96,480 new cases will be diagnosed
and about 7,230 people will die from melanoma in 2019. Melanoma has an overall
mortality rate of approximately 20% and is responsible for 80% of all deaths related
to cutaneous tumors. The high mortality rate associated with melanoma is a result
of its remarkable metastatic potential (Paluncic et al., 2016).
Melanoma Biology
Melanoma results from the transformation of pigment cells, namely
melanocytes. Melanocytes are neural crest-derived cells that during development
migrate to the skin where they reside in the basal layer of the epidermis and hair
follicles (Colombo et al., 2011). Melanocytes represent a small population within
the skin where there are 10 keratinocytes to each melanocyte (Kanitakis, 2002).
Melanocytes are specialized in the production of melanin, the main natural pigment
in the skin, which affords a protective effect to keratinocytes against ultraviolet
(UV)-induced DNA damage (Costin and Hearing, 2007). Under UV exposure
keratinocytes produce α-Melanocyte stimulating hormone (αMSH), which binds to
the melanocortin 1 receptor (MC1R) receptor in melanocytes triggering the
production of melanin that is eventually delivered to keratinocytes (Schauer et al.,
1994; Chakraborty et al., 1996). Melanocytes can produce two different types of
melanin: eumelanin, a dark-brown pigment that protects against UV damage and
pheomelanin, a yellow-red pigment that is less protective. Individuals with red hair
2

and fair skin phenotype harbor MC1R variants and therefore are more susceptible
to the deleterious effects of UV radiation (Lo and Fisher, 2014).
The major risk factor for melanoma is sun exposure which is represented by
the astounding number of UV-signature mutations, such as C>T and G>T, present
in melanoma tumors (Lawrence et al., 2013). In fact, melanoma has a median
number of >10 mutation/megabase of DNA, which makes it the top tumor type with
respect to frequency of somatic mutations (Alexandrov et al., 2013; TCGA, 2015).
Very intriguing is the observation that many UV-associated alterations are
passenger mutations and have no biological effect as opposed to driver mutations
which are oncogenic (Hawryluk and Tsao, 2014). Common mutations found in
melanoma, namely BRAFV600E, NRASQ61L, KITV559A, and GNA11Q209L, lack the
typical UV-signatures (Hodis et al., 2012). Nevertheless, the fact that common
mutations found in melanoma lack UV-signature does not mean sunlight is not
implicated in the mutation load characteristic of melanoma (Schadendorf, Fisher,
et al., 2015). Secondary mutations can be generated by the interaction of melanin
with UV light and indirectly modify the DNA (Noonan et al., 2012). It should be
noted though that genetic alterations in tumor suppressor genes like tumor protein
53 (TP53), phosphatase and tensin homolog (PTEN), and cyclin dependent kinase
inhibitor 2A (CDKN2A) have a high number of UV-induced mutations (Hodis et al.,
2012).
Depending on the amount of cumulative UV-exposure melanomas can be
classified as non-chronically sun damaged (non-CSD) or chronically sun damaged
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(CSD). Non-CSD melanomas are more prevalent in young patients and arise in
regions of the body with intermittent sun exposure. Non-CSD melanomas harbor
the BRAFV600E mutation and a modest level of mutation burden. Older patients that
have been continually exposed to UV radiation tend to develop CSD melanomas,
which possess an enormous mutation load and carry different genetic alterations,
namely BRAFnonV600E, NRAS and neurofibromatosis type 1 (NF1) mutations (Shain
and Bastian, 2016).
Genetic alterations during melanoma development
Melanoma development has long been depicted as a linear progression (Figure
1.1) starting from benign lesions such as melanocytic and dysplastic naevi that
transform into melanoma in situ which eventually evolves to more malignant
lesions like invasive and metastatic melanoma (Shain and Bastian, 2016). A
melanocytic naevus is characterized by limited proliferation of melanocytes
through the constitutive activation of mitogen-activated protein kinase (MAPK)
signaling pathway initiated by BRAFV600E mutation (Shain et al., 2015). Neavi
formation resulting from Braf activation has been elegantly demonstrated by a
mouse model in which only melanocytes harbor the BrafV600E mutation. These
mutant mice developed lesions very similar to melanocytic naevi found in humans
(Dankort et al., 2009). It is widely accepted that melanocytic naevus is the benign
precursor of non-CSD melanoma because of the fact that both types of lesions
share high amounts of BRAFV600E mutations (Pollock et al., 2003). On the other
hand, CSD melanomas, which have BRAFnonV600E mutations and tend to arise from
de novo lesions, have no evolutionary connections with melanocytic naevi (Shitara
4

et al., 2014). In the absence of additional genetic alterations melanocytic naevi are
directed to a senescence-like stage defined by cell cycle arrest and abrogation of
cell proliferation. The BRAFV600E mutation is an important trigger of the senescence
observed in melanocytic naevi illustrating the well-known oncogene-induced
senescence phenomenon (Damsky and Bosenberg, 2017). The immune system
may also enhance senescence as activation of BRAF stimulates the secretion of
pro-inflammatory mediators interleukin 6 (IL-6) and interleukin-8 (IL-8) (Kuilman et
al., 2008). Interestingly, the expression of these inflammatory mediators are
augmented in melanocytic naevi when compared to more aggressive lesions
(Ahmed et al., 1995).
The vast majority of melanocytic naevi remain dormant and never give rise to
melanoma. It is estimated that during a man’s lifetime there is a risk of 1/3,000 that
a nevus will progress to melanoma and for women the odds are even lower
(1/11,000) (Tsao et al., 2003). Melanocytic naevi rarely acquire mutations in the
telomerase reverse transcriptase (TERT) promoter and heterozygous alteration in
the CDNK2A locus, which activate telomerase and disturb the cell cycle
checkpoints, respectively (Shain et al., 2015). These alterations result in the
formation of an intermediate lesion between benign and malignant melanoma
called dysplastic naevus (Elder et al., 1980). Mutations in the TERT promoter are
considered one of the earliest secondary mutations present in the naevus and
roughly 80% of dysplastic naevi exhibit these alterations (Shain et al., 2015).
Individuals with germline variants of CDNK2A tend to develop numerous de novo
dysplastic naevi leading to dysplastic nevus syndrome (Shain and Bastian, 2016),
5

and have 70% of chance to develop familial melanomas during their lifetime (De
Snoo and Hayward, 2005). Some dysplastic naevi developed sporadically have
greater number of NRAS mutation compared to the amount of BRAFV600E mutation
present in the melanocytic naevi suggesting that in some case melanocytic and
dysplastic naevi do not follow the same evolutionary pathway (Shain et al., 2015).
Immune surveillance seems to be tightly associated with emergence and growth
of naevi. In a condition termed eruptive naevi individuals abruptly develop
numerous naevi harboring the BRAFV600E mutation and the phenomenon is
particularly common in immunosuppressed patients (Sekulic et al., 2010).
Transformed melanocytes with excessive proliferation restricted to the
epidermis is a characteristic of melanoma in situ. In addition to the heterozygous
mutations in CDKN2A and alterations in the TERT promoter in situ melanomas
have increased mutations affecting downstream effectors of MAPK signaling
pathway (Shain and Bastian, 2016). Approximately 50% of in situ melanomas have
the BRAFV600E mutation, and 30% harbor the NRASQ161L mutation. (Omholt et al.,
2002, 2003; TCGA, 2015). Interestingly, those mutations are mutually exclusive
implying an absence of selective advantage in harboring many alterations in the
MAPK signaling pathway (Damsky and Bosenberg, 2017). Inactivation of tumor
suppressor gene NF1, a negative regulator of RAS, is the third most common
genetic alteration in melanomas and is most prevalent in older patients
(Krauthammer et al., 2015; TCGA, 2015). There is a fourth subtype of melanoma
that does not harbor either of those three classical mutations (BRAF, NRAS or
NF1) in the MAPK signaling pathway and therefore is considered triple wild-type
6

melanoma. Mutations in the receptor tyrosine kinase KIT and in the α subunits of
G-protein GNA11 and GNAQ are more frequent in triple wild-type melanomas
(TCGA, 2015). In situ melanoma may endure for decades gathering a variety of
mutations before acquiring the ability of breaking the epidermis and invading the
surrounding tissues (Shain and Bastian, 2016).
Once melanoma is able to occupy the dermis it is considered to be at the
invasive stage. The level of invasiveness is associated with reduced survival and
used as a prognostic factor (Schadendorf, Fisher, et al., 2015). A crucial genetic
alteration found in early invasive melanomas is the inactivation of the second copy
of CDKN2A (Shain et al., 2015). Alternative splicing of CDKN2A locus produces
two different proteins, p16INK4A, and p14ARF (or p19ARF in mice), that are considered
major tumor suppressors in melanoma (Damsky and Bosenberg, 2017). The
protein p16INK4A phosphorylates Rb preventing cell cycle progression in G1/S
phase (LaPak and Burd, 2014) while p14ARF inhibits p53 degradation by MDM2
(Maggi et al., 2014). A mouse model with the BrafV600E mutation in combination
with Cdkn2a inactivation develops melanomas with 100% of penetrance as mice
age (Damsky et al., 2015) and transgenic mice harboring the NrasQ61K mutation
and homozygous deletion of Ink4a gene develop invasive melanomas in six
months (Ackermann et al., 2005).
Later in the progression of the primary tumor the phosphatase PTEN is often
lost as metastatic melanomas have high frequency of PTEN inactivation
(Reifenberger et al., 2000). Silencing of PTEN associated with the BRAFV600E

7

mutation is observed in 80% of melanoma cell lines (Tsao et al., 2004) and 40%
of melanoma patients (Hodis et al., 2012). Transgenic mice have confirmed that
BrafV600E mutation alone is not sufficient to produce invasive melanoma, but when
it is associated with the Pten deletion, mice develop melanomas with high
penetrance that metastasize to lymph nodes and lungs (Dankort et al., 2009). The
protein p53 is another tumor suppressor altered during late stages of melanoma
(Shain and Bastian, 2016). Disruption of p53 in melanoma is lower compared to
other types of solid tumors but mutations in the TP53 gene are more frequent in
metastatic lesions when compared to primary melanomas (Stretch et al., 1991).
Melanoma Metastasis
Melanoma is referred as metastatic after tumorigenic cells leave the primary
tumors and disseminate to distant sites in the body. Once melanoma becomes
metastatic, the patients has a very poor prognosis with the 1-year overall survival
rate around 25% and the median survival of 6.2 months (Korn et al., 2008).
Melanoma generally establishes secondary lesions in brain, lymph nodes, skin and
lung (Murakami, Cardones and Hwang, 2004), the latter being the most common
tissue affected in approximately 40% patients with metastatic disease (Balch et al.,
1983). The nearest draining lymph to primary tumors is generally thought to be the
first site of dissemination of metastatic cells and the colonization of visceral organs
happens afterwards (Shain and Bastian, 2016). The presence of melanoma cells
in the sentinel lymph node has long been accepted as prognostic factor for patients
(Balch et al., 2009). Yet, the complete resection of the sentinel lymph node does
not seem to improve patient survival (Kingham et al., 2010).
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Recently it has been suggested that metastasis might be formed earlier in the
history of the primary tumor and the idea challenges the classical paradigm of
linear progression of melanoma metastasis formation (Gassenmaier et al., 2017).
Currently, there are some indications that metastasis formation takes place in
parallel to the development of the primary tumor (Damsky, Theodosakis and
Bosenberg, 2014; Sanborn et al., 2015), although the molecular mechanisms
underlying the parallel progression model are not established yet (Figure 1.1).
Patients with no signs of metastatic disease have melanoma cells (Reid et al.,
2013) and even benign melanocytes detected in their bloodstream (Hall et al.,
2012). In the condition termed nodal naevi, melanocytes carrying BRAFV600E
mutation are found in lymph nodes (Taube et al., 2009) and nodal naevi have been
detected in patients with no melanoma disease (Bautista, Cohen and Anders,
1994). Further observation supporting the parallel progression model of melanoma
metastasis includes the fact that 5% of patients with metastatic disease have no
detectable primary tumor (Giuliano, Moseley and Morton, 1980). It is reasonable
to speculate that metastatic features are established during benign stages of
melanoma development rather than acquired during progression, but the
development of fully metastatic phenotype would require further mutations gained
later during tumorigenesis (Shain and Bastian, 2016). The linear and parallel
models of melanoma dissemination are not necessarily mutually exclusive since
both pathways are likely to generate relevant metastatic disease (Damsky,
Theodosakis and Bosenberg, 2014).
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1.2.

Tumor Microenvironment

Cancers had long been viewed as an assembly of heterogeneous transformed
cells. The reductionist view of tumors has changed over the past decades to a
more complex landscape. Presently, a tumor is seen as an “organ” where an
elaborate and bidirectional interaction between cancer cells and non-malignant
cells from the surrounding stromal tissue takes place (Hanahan and Weinberg,
2011). Inside these “organs” there is a complex network called the tumor
microenvironment (TME) that includes not only the cancer cells, but also the
tumor stroma which is a milieu that comprises non-neoplastic cells, extracellular
matrix (ECM), and the signaling molecules they are embedded in (Spano and
Zollo, 2012). The cellular component of the TME is diverse and include fibroblasts,
endothelial cells, and a variety of immune cell populations namely, macrophages,
neutrophils, myeloid derived suppressor cells (MDSC), dendritic cells (DC), natural
killer (NK) cells, and T and B lymphocytes subtypes (Quail and Joyce, 2013).
The TME is a not an inert component but rather, a continuously evolving system
modulated by oncogenic and environmental signals and, in response to the
metamorphic TME, tumor cells are also modified and become more aggressive
(Binnewies et al., 2018). Thus, it is now well established that the TME plays a
crucial role during tumor development, supporting tumor growth, invasion and
metastasis (Spano and Zollo, 2012). In some cancers the malignant cells represent
only 30% of all cell types existing in the TME (Becker et al., 2013). Furthermore,
the amount of different cell populations in the tumor stroma varies drastically when
different tumors are compared or even among patients harboring the same type of
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cancer. Indeed, each tumor has its own “TME fingerprint” that can be addressed
for prognostic and therapeutic purposes (Liu, Workman and Vignali, 2016).
Tumor formation and development is associated with a deregulated
microenvironment as observed by the increased incidence of cancers in individuals
that experience chronic inflammation or immunosuppression (Palucka and
Coussens, 2016). Patients with long-term colitis have seven times more chance to
develop colon cancer than those with no inflammation in their colon (Beaugerie et
al., 2013). Lung and skin cancer arise more frequently in organ transplant
recipients that are under immunosuppressive regimen (Stewart et al., 1995). Upon
the initial transformation of cells in a tissue, the tumorigenic cells recruit cancerassociated fibroblasts (CAFs). Cancer-associated fibroblasts establish a crosstalk
with the tumorigenic cells based on chemokines and growth factors, which in turn
attract immune cells to participate in the network. Immune cells play ambiguous
roles during tumorigenesis, either antagonizing or supporting tumors and the
balance between tumor suppressing or promoting immune cells will determine the
fate of tumor progression (Spano and Zollo, 2012).
Emerging tumor cells overexpress mutated or new antigens that are collectively
called tumor-associated antigens (TAA). Tumor-associated antigens can be
recognized by DCs and presented to CD4+ Helper T cells, which activate CD8+
cytotoxic T cells (CTLs) that will eventually eliminate the cancer cells (Lee, 2017).
Cancer cells can also reduce their own immune recognition deregulating MHC-I
expression. However, NK cells can detect the missing self in the tumors and
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destroy them (Morvan and Lanier, 2016). The elaborate network of immune cells
devoted to finding and removing cancer cells is termed tumor immunosurveillance
and is constantly monitoring every host tissue and keeping the body clear of cancer
cells (Grivennikov, Greten and Karin, 2010; Hanahan and Weinberg, 2011). The
tumor immunosurveillance hypothesis is supported by the observation that
immunocompromised mice lacking different populations of lymphocytes are more
susceptible to induced and spontaneous tumors than their immunocompetent
counterparts (Shankaran et al., 2001).
The relationship between cancer and inflammation has long been
acknowledged. In the mid nineteenth century, it was already demostrated that
tumors have a high incidence of leukocyte infiltrates (Balkwill and Mantovani,
2001). Since immune cells can detect and destroy cancer cells, the presence of
inflammation in neoplastic contexts had been interpreted as a frustrated attempt
by the immune system to eliminate the tumor. Some authors described tumors as
wounds that never heal (Flier, Underhill and Dvorak, 1986). Counterintuitively, over
the past decades it has become clear that inflammation may endow tumorigenesis.
The inflammatory milieu is characterized by large amounts of growth, survival and
angiogenesis factors, which promote tumor growth, evasion of growth suppression
and angiogenesis, respectively. The large number of reactive oxygen species
generated during inflammation may also increase the genetic instability through
mutagenic events in the tumor cells (Condeelis and Pollard, 2006; Hanahan and
Weinberg, 2011).
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Inflammation alone is not sufficient for tumor progression because of the
intense cell recruitment of immune cells to the TME potentially exposes tumor cells
to immune detection and elimination. Many of the inflammatory mediators are also
related to the recruitment and activation of immunosuppressive cells such as
MSDC and regulatory T cells (Tregs) (Umansky and Sevko, 2012). These cells
show remarkable immunosuppressive and anti-inflammatory activities and are
able to disturb many mechanisms of immunosurveillance, including but not
restricted to the impairment of T cell activation, antigen presentation by DC and
interruption of NK cells cytotoxicity (Quail and Joyce, 2013). Therefore, the
recruitment of immune cells to the TME is highly advantageous to tumor cells given
that inflammatory cells foster tumor progression while immunosuppressive cells
make those anti-tumor recruited cells unable to recognize and kill cancer cells
(Hanahan and Weinberg, 2011).
Immunoediting explains the contradictory interaction of immune cells in the
TME throughout tumor development and progression. The immunoediting concept
was derived from the findings that immunocompromised mice develop tumors that
are more immunogenic (more easily detected by the immune cells) than tumors
arising in immunocompetent mice (Shankaran et al., 2001). According to the
immunoediting concept, the host immune system prevents tumor formation while
modulating tumor immunogenicity. Immunoediting happens through a sequence
of stages starting from elimination, evolving to equilibrium and culminating in the
escape phase. The elimination phase is when the immunosurveillance system
detects and eradicates emerging tumors. Rarely, tumors cells that subsist the
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forces of immunosurveillance are kept dormant during the equilibrium phase. The
equilibrium phase is probably the longest phase of the immunoediting process.
Throughout equilibrium phase the immune system selects and edits the
immunogenicity of tumors cells. During the escape phase tumor cells that became
less

immunogenic

form

visible

tumors,

further

enhanced

by

the

immunosuppressive setting installed in TME (Schreiber, Old and Smyth, 2011).
The TME has recently attracted much attention for its therapeutic opportunities.
For many years the approach to treat patients with malignant tumors depended
solely on targeting tumor cells. Tumors initially respond to targeted therapies but
as a consequence of the genetic instability of malignant cells they become
resistant to treatments. Presumably, a more effective alternative is to target the
stromal cells in the TME. Non-transformed cells are genetically stable and offer
reduced opportunity to circumvent targeted treatments (Quail and Joyce, 2013).
During the last few years approaches aiming to reprogram the TME and shift the
balance toward a more anti-tumorigenic phenotype have considerably improved
patients’ outcome. Many of these strategies, called immunotherapy, are meant to
boost the host’s immune system to combat cancer. Immunotherapy has produced
exciting results and in the next decade it is likely that 60% of patients with
advanced tumors will be treated with immunotherapy (Ledford, 2014).
Cell types
Cells in the TME can be classified as either pro-tumorigenic or anti-tumorigenic.
Among pro-tumorigenic cells there are macrophages, neutrophils, T and B cells,
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and MDSCs. The anti-tumorigenic cells are CTLs and NK cells (Hanahan and
Weinberg, 2011). A more complex classification is defined by the dual role of
immune cells in the TME: immune cells with an anti-tumorigenic role are “type 1
cells” whereas those with a pro-tumorigenic role are “type 2 cells”. The CD4 + T
helper cells TH1, neutrophils N1, and macrophages M1 are all tumor-inhibitory
cells. In contrast, CD4+ helper cells TH2, neutrophils N2 and macrophages M2 are
all tumor-promoting cells (Becker et al., 2013). So far, NK cells have not been
described as playing pro-tumorigenic roles in the TME (Smith and Kang, 2013).
The “type 1” and “type 2” classification of immune cells in the TME is very useful
for describing the basic concepts underlying the TME. However, the classification
should be viewed with caution because the complexity of TME cannot be reduced
to an all or none framework (Quail and Joyce, 2013). Another dichotomous
classification of the TME is focused on its global immunological phenotype.
Tumors with low number of anti-tumorigenic cells such as CTL, NK and T H1
lymphocytes, few DCs and high number of immunosuppressive cells (i.e., MSDC
and Tregs) are considered “cold” tumors. Conversely, “hot” tumors are highly
inflamed and enriched with effector anti-tumor cells and antigen presenting cells
(APCs) and therefore are likely to have a better response to immunotherapies
(Nagarsheth, Wicha and Zou, 2017; Binnewies et al., 2018). A diagrammatic
representation of the many cell types and their interactions in the TME is shown in
Figure 1.2.
.
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1.2.1.1.

Anti-tumorigenic immune cells

Mature DCs are very efficient APCs that initiate strong anti-tumor response
upon interaction with lymphocytes (Nagarsheth, Wicha and Zou, 2017). Dendritic
cells activate lymphocytes when TAAs are presented in presence of co-stimulatory
signals. The best characterized co-stimulatory signal system is CD28-B7; CD28 is
expressed by T cells while B7 is expressed in the DC surface. The protein B7 can
also bind to the inhibitory receptor cytotoxic T lymphocyte associated protein 4
(CTLA-4), but in binding to CTLA-4 prevents T cell activation (Andersen et al.,
2006). When DCs loaded with TAA encounter naïve CD8+ T cells they promote T
cell differentiation into TAA-specific CTLs. A similar differentiation process
happens when DCs find naïve CD4+ T helper cells but in this case T helper cells
can differentiate into subpopulations with different phenotypes including T H1 and
TH2 (Palucka and Coussens, 2016). Dendritic cells induce the polarization of CD4 +
T helper cells towards TH1 or TH2, a process that relies on (interleukin 12) IL-12
availability. Antigen presentation in presence of IL-12 generates T H1 cells. In
contrast, when antigens are presented in absence of IL-12, CD4+ T helper cells
differentiate into TH2 cells (Banchereau and Palucka, 2005).
The TH1 polarized CD4+ T helper cells are associated with destruction of
malignant cells. A large number of TH1 cells is correlated with good outcome for
patients (Galon et al., 2006). The TH1 cells work in coordination with DCs to
promote the activation of tumor-specific CTLs through cross-presentation of TAAs
(Dunn, Old and Schreiber, 2004). Another anti-tumor mechanism of T H1 cells is
via the production of interferon-γ (IFN-γ), which is one of the main modulators of
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the host response against tumors (Ikeda, Old and Schreiber, 2002). Interferon-γ
derived from TH1 cells polarizes monocytes towards M1 phenotype (Mantovani et
al., 2008) and activates the cytotoxic activity of macrophages as well as CTLs
facing tumors cells (Ikeda, Old and Schreiber, 2002; Becker et al., 2013).
Cytotoxic T cells (CTLs) is considered the principal cell type of anti-tumor
immunity (Appay, Douek and Price, 2008) and, not surprisingly, tumors with high
infiltrates of CTLs are associated with improved prognosis (Clemente et al., 1996;
Prall et al., 2004; Bachmayr-Heyda et al., 2013). Cytotoxic T cells have two
strategies to kill cancer cells that require direct cell-cell contact. The first
mechanism is through the secretion of granules of perforin and granzyme B (GZB)
in the extracellular space, the other apparatus is via Fas ligand/Fas receptor. Both
approaches trigger apoptosis in the target cancer cell and must be tightly regulated
to prevent accidental killing of the CTLs themselves or other neighboring cells.
Cytotoxic T cells also secret cytokines like IFN-γ and TNF-α that similarly activate
apoptosis in the target cells (Andersen et al., 2006). Upon long-lasting exposure
to TAAs, CTLs might enter in a stage called exhaustion, characterized by reduced
proliferation and cytotoxic activity as well as augmented expression of inhibitory
receptors such as CTLA-4 and programmed cell death-1 (PD-1). The expression
of inhibitory receptor ligands by tumor and stromal cells in the TME prevents CTL
activity. Recently, immunotherapy treatments aiming to block the expression of
immune checkpoint inhibitors have successfully strengthened tumor infiltrating
CLTs and provided durable anti-tumor response in patients with advanced tumors
(Zarour, 2016).
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Natural killer (NK) cells are cells from the innate immunity system that also have
strong cytotoxic activity against tumor cells (Corthay, 2014). High tumor incidence
in animal models (Talmadge et al., 1980) and patients with NK cell deficiencies,
supports the pivotal role of NK cells in immunosurveillance (Roder et al., 1980).
Likewise CTLs, NK cells kill tumors cells using granzymes and perforin granules
as well as death receptor/ligand pathways. The NK cells can discriminate between
healthy and cancer cells on the basis of the balance between inhibitory and
activating receptors. Inhibitory receptors detect self-major histocompatibility
complex-I (MHC-I) in normal cells and prevent the activation of NK cells (Morvan
and Lanier, 2016). Cancer cells recurrently downregulate MHC-I expression so
that they can escape CTL detection. The NK cells detect the missing self on tumors
cells that escaped CTLs control and this process triggers NK activity. Some cancer
cells maintain MHC-I expression and express ligands to NK’s activating receptors
(i.e. NKG2D) and the binding of these ligands also stimulate NK cytotoxic activity
(Muenst et al., 2016).
1.2.1.2.

Pro-tumorigenic immune cells

Tumor-associated macrophages (TAMs) are major contributors to tumor cell
migration, invasion and metastasis. They are mainly localized in the tumor edge
where they facilitate tumor invasion (Condeelis and Pollard, 2006). Indeed, there
is a positive correlation between augmented metastatic incidence and high TAM
infiltration (Hanada et al., 2000). Tumor-associated macrophages mainly show M2
phenotype in the TME (Rhee, 2016) and are recognized as the main source of
matrix-degrading proteases which promote tumor cell invasion (Quail and Joyce,
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2013). In breast and pancreatic cancer, TAMs are associated with production of
metalloproteinases (MMP) MMP-2 and MMP-9 (Hagemann et al., 2004) as well as
cathepsin B and S secretion (Gocheva et al., 2010). Tumor-associated
macrophages also influence tumor invasion through a signaling loop involving EGF
and CSF-1. Epidermal growth factor (EGF) secreted by TAMs interacts with its
receptor on tumor cells and in addition to cell motility, promotes the tumor secretion
of CSF-1, which in turn stimulates TAMs to produce more EGF (Goswami et al.,
2005). Additionally, TAMs have reduced antigen presentation capacity and
produce immunosuppressive cytokines IL-10 and TGF-β (Muenst et al., 2016).
Myeloid derived suppressor cells (MDSC) are immature cells with potent
immunosuppressive features detected in tumors of murine models and patients
with different types of tumors. In mice, MDSCs are defined by the co-expression
of macrophage (CD11b+) and neutrophil (Gr1+) markers, but in humans, their
characterization is more complex since human MDSCs are comprised of
populations with diverse phenotypes (Spano and Zollo, 2012). The MDSCs can
be distinguished as either monocytic (M-MDSC), that are more like monocytes, or
polymorphonuclear (PMN-MDSC), resembling neutrophils. M-MDSCs have
stronger immunosuppressive capabilities than PMN-MDSCs which explains why
M-MDSCs are abundant in tumors (Kumar et al., 2016). The MSDCs have different
mechanisms to disturb immunosurveillance and orchestrate immunosuppression
in the TME. The MDSCs impair T cell activity by the expression of arginase (ARG1). Arginase consumes L-arginine and the depletion of this essential amino acid
from the TME causes downregulation of T cell receptor complex and proliferative
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arrest. The expression of iNOS enzyme by MDSCs creates oxidative stress which
also affects T cell function (Gabrilovich, Ostrand-Rosenberg and Bronte, 2012).
Myeloid derived suppressor cells also prevent M1 polarization (Sinha, Clements
and Ostrand-Rosenberg, 2005) and disrupt NK cell cytotoxicity (Liu et al., 2007).
Moreover, MDSCs promote the conversion of naïve CD4 + T cells into Tregs as well
as their expansion, and these processes might be dependent on the production of
immunosuppressive cytokines interleukin-10 (IL-10) and transforming growth
factor β (TGF-β) (Huang et al., 2006).
Regulatory T cells (Tregs) are immunosuppressive cells that during
homeostasis prevent excessive immune responses and promote self-tolerance,
but in the context of tumorigenesis, Tregs may allow the escape of tumor cells from
immunosurveillance (Lee, 2017). The association of Tregs with patient outcome is
very controversial. In many cancers, including melanoma, the accumulation of
Tregs is correlated with poor prognosis (Knol et al., 2011). Conversely, when tumor
initiation is associated with chronic inflammation (i.e., colorectal cancer) Tregs
have a protective effect and therefore high numbers of this immunosuppressive
cell predicts improved survival (Frey et al., 2010). Treg cells exert their repressive
role onto tumor-specific lymphocytes via a variety of mechanisms including
production of immunosuppressive cytokines IL-10 and TGF-β, eliminating IL-2
which is an essential cytokine for CTLs expansion and expressing the immune
checkpoint inhibitor CTLA-4, a common target in immunotherapy (Schreiber, Old
and Smyth, 2011).
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1.2.1.3.

Non-immune stromal cells

Cancer-associated fibroblasts (CAFs) are the pioneer cells recruited to the
TME and the most numerous cell population in the tumor stroma (Spano and Zollo,
2012). CAFs, sometimes referred as myofibroblasts, are different from normal
fibroblasts and detectable by the expression of α-smooth muscle actin (α-SMA)
(Egeblad, Nakasone and Werb, 2010). The origin of CAFs present in the TME is
still unclear. Some findings have suggested that fibroblasts may arise after
epithelial cells experience epithelial-to-mesenchymal transition (EMT) (Petersen et
al., 2003), whereas another study presented the possibility of endothelial cells
generating fibroblasts after undergoing endothelial-to-mesenchymal transition
(EndMT) (Zeisberg et al., 2007). Co-culture of cancer cells with normal fibroblasts
or CAFS has demonstrated that CAFs are important for tumor initiation (Olumi et
al., 1999) and invasive phenotype (Dimanche‐Boitrel et al., 1994). Cancerassociated fibroblasts have many secretory functions that promote tumor growth
and are considered the main source of growth factors in the TME (Quail and Joyce,
2013). For example, hepatocyte growth factor (HGF) derived from CAFs provides
the oncogenic signal for tumor cell proliferation. In addition, CAFs modify the ECM
though the secretion of many ECM components (tenascin C, collagen I and II) as
well as matrix metalloproteinases (MMPs) accelerating tumor progression (Kalluri
and Zeisberg, 2006). Furthermore, CAFs modulate the recruitment of different
populations of immune cells to the TME and ablation of CAFs from the TME
reduces the amounts of TAMs, MDSCs and Tregs (Liao et al., 2009). Cancerassociated fibroblasts are also an important supplier of vascular endothelial growth
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factor (VEGF) which underscores the pivotal function of fibroblasts during tumor
angiogenesis (Fukumura et al., 1998).
Endothelial cells are also a critical cellular component of the TME. Besides their
vascular function in supplying nutrients to the TME, they have the capacity to
create new routes for recruitment of immune cells and metastatic cells dispersion
(Smith and Kang, 2013). Pro-angiogenic factors induce the sprouting of new
vessels from existing ones in a process known as angiogenesis (Fang and
DeClerck, 2013). In the earlier 1970s it was proposed that tumor development
relies on angiogenesis (Sherwood, Parris and Folkman, 1971) and since then
angiogenesis has been considered a hallmark of cancer (Hanahan and Weinberg,
2011). Vascular endothelial growth factor is the major regulator of angiogenesis
and its production in the TME results in endothelial cell migration and proliferation
as well as increased vascular permeability (Hida et al., 2018). Tumor endothelial
cells (TECs) are very different from their normal counterparts in many
characteristics including gene expression profiles, chromosomal abnormalities and
proliferative and migratory features (Maishi and Hida, 2017). Tumor endothelial
cells from tumors with different metastatic potential are also distinct suggesting
that endothelial cells are involved in metastasis formation (Ohga et al., 2012).
When TECs derived from highly metastatic tumors are co-injected with poorly
metastatic cancer cells the metastatic potential of these tumor cells is enhanced
(Maishi et al., 2016).
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Cytokines
The different cell populations present in the TME establish a complex
communication network and much of the cross-talk is regulated by cytokines that
promote tumor growth and progression (Burkholder et al., 2014). The term cytokine
was primarily used to describe the group of secreted molecules derived from
hematopoietic cells. A sophisticated concept suggests that cytokines are
molecules produced by a variety of cell types and used for cell-to-cell
communication. These molecular messengers are major modulators of many
physiologic and pathologic events including hematopoiesis, immune response,
angiogenesis, wound healing and cancer (Huang et al., 2012). There are two
fundamental features of cytokines that influence their microenvironmental action.
Cytokines are pleiotropic molecules meaning that the same cytokine can produce
diverse effects in different cell types. Cytokines are also redundant molecules, thus
the action of different cytokines may have the same outcome in a cell population
(Ozaki and Leonard, 2002).
Cytokines play a decisive role during the polarization and biological action of
some immune cells present in the TME. An integrated system of cytokines
educates neutral and immature immune cells towards tumor-inhibitory or tumorpromoting effector phenotypes. Tumor microenvironment education is a
consequence of intrinsic plasticity of immune cells under the influence of
stimulatory or suppressive cytokines (Quail and Joyce, 2013). Macrophages and
CD4+ T cells are particularly susceptible to this molecular communication and in
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response to cytokines existing in the TME they differentiate into either antitumorigenic or pro-tumorigenic subtypes (Burkholder et al., 2014).
Macrophage polarization has been well-described in many studies. Monocytes,
the precursors of macrophages, are very sensitive to the first cytokines they
encounter in the TME (Figure 1.3). Upon arrival in the TME, if monocytes are
initially exposed to the cytokine IFN-γ they differentiate into M1 macrophages
(Grivennikov, Greten and Karin, 2010). Macrophages M1 secrete many proinflammatory cytokines, namely IL-1, IL-6, IL-12, and TNF-α (Rhee, 2016).
Conversely, if after arriving in the TME monocytes first encounter the cytokines IL4, IL-10, IL-13 or TGF-β (Allavena et al., 2008) they are polarized towards M2
phenotype and produce anti-inflammatory cytokines TGF-β and IL-10 (Sica,
Allavena and Mantovani, 2008). Macrophage phenotype is very plastic therefore it
is also possible that, as a result of cytokine re-education, M2 macrophages switch
towards M1 phenotype (Quail and Joyce, 2013).
The CD4+ helper T cells can be distinguished into many subtypes depending
on their cytokine profile (Figure 1.4). The differentiation of naïve CD4 + T cell into
effector subsets found in the TME is orchestrated by APC-derived cytokines during
antigen presentation. Remarkably, the specific cytokines of a subgroup can
reinforce its differentiation while prevent the differentiation into a different subtypes
(Gutcher and Becher, 2007). Initially, it was believed that naïve CD4 + T cells would
only be able to polarize towards either TH1 or TH2. When APCs present antigen to
naïve CD4+ T cells in presence of IL-12, TH1 cells are generated (Seder et al.,
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1993) and TH1 cells will prominently secrete IFN-γ in addition to TNF-α, IL-2 and
IL-12 cytokines (Burkholder et al., 2014). On the other hand, if there is no IL-12
during antigen presentation, naïve CD4+ T cells start to secrete IL-4 and
differentiate into TH2 cells (Swain et al., 1990), which in addition to IL-4 also
produce IL-5 and IL-10 cytokines (Moss et al., 2004). Later it was discovered that
TGF-β is also an important regulator of naïve CD4 + T cell polarization. Secretion
of TGF-β alone by APC generates the immunosuppressive subtype Treg that
produces IL-10 and TGF-β (Chen et al., 2003). However, when TGF-β is
supplemented with IL-6, naive CD4+ T cells polarize towards the pro-inflammatory
subtype TH17 which produces IL-17 (Veldhoen et al., 2006). The TH17 cells
execute their anti-tumor actions recruiting more CTLs, NKs and DCs to the TME
(Nagarsheth, Wicha and Zou, 2017).
A cytokine network comprised of the canonical pro-inflammatory cytokines IL1, IL-6, and TNF-α as well as TH1-associated cytokines IL-12 and IFN-γ
coordinates the effective anti-tumor immune response accountable for tumor
immunosurveillance (Figure 1.5). Tumor-specific T H1 cells produce the
proliferative cytokine IL-2 in addition to IFN-γ, a cytokine that polarizes
macrophages towards M1 phenotype. Polarized M1 macrophages secrete IL-12,
that enhances TH1 phenotype, and also a series of pro-inflammatory cytokines
(i.e., IL-1, IL-6 and TNF-α) that have tumoricidal activity (Haabeth, Bogen and
Corthay, 2012). Interleukin-1 cooperates with IL-2 to promote proliferation of CTLs
and NK cells (Aribia et al., 1987) and enhances the antigen-presenting functions
of DCs (Burkholder et al., 2014). Interleukin-6 increases CD4+ and CTL anti-tumor
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activity and prevents tumor progression (Mulé et al., 1992). Tumour necrosis factor
α (TNF-α) is crucial for NK recruitment to the TME and mice lacking TNF-α have
defective tumor immunosurveillance (Smyth et al., 1998). Additionally, M1
macrophages produce chemokines CXCL9, CXCL10 and CXCL11 that attract
more anti-tumorigenic cells to the TME (Haabeth, Bogen and Corthay, 2012).
Cytokines participate in the conversion from tumor-inhibitory to tumorpromoting TME. The balance shifted towards anti-inflammatory cytokines rather
than pro-inflammatory cytokines creates an immunosuppressive milieu that allows
escape from tumor immunosurveillance (Burkholder et al., 2014). Interleukin-10
and TGF-β produced by different cell populations are the two major regulators of
immunosuppression in the TME (Figure 1.6) (Kim et al., 2006).
Interleukin-10 is an immunosuppressive cytokine that allows escape of tumor
cells from immune destruction in the TME (Mannino et al., 2015). High expression
of IL-10 is considered a poor prognostic factor for patients with melanoma
(Dummer et al., 1995; Nemunaitis et al., 2001). Type 2 lymphocytes (TH2) seem to
be the main source of IL-10 in the TME, but other cells types including Tregs,
TAMs, DC, NK and tumors cells also produce IL-10. The major mechanism of IL10 immunosuppression is the impairment of antigen presentation (Sato et al.,
2011). Interleukin-10 downregulates co-stimulatory (B7) (Ding et al., 1993) and
MHC molecules of APCs (de Waal Malefyt et al., 1991). Interleukin-10 also induces
immunosuppressive activity of Tregs and suppresses pro-inflammatory T H17 cells
(Oft, 2014). Further, in vitro studies have shown that IL-10 turns CTLs
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unresponsive to antigens (Groux et al., 1998) and inhibits the production of IFN-γ
cytokine in TH1 (Taga and Tosato, 1992) and NK cells (Peppa et al., 2010). Some
studies have

challenged the paradigm that IL-10 exclusively supports tumor

development. In some contexts, IL-10 may play anti-tumorigenic roles by
increasing the proliferation of CTLs (Chen and Zlotnik, 1991) and NK cell cytotoxic
activity (Parato et al., 2002).
Similar to the ambiguous role of IL-10, the role of immunosuppressive cytokine
TGF-β in tumor development is also paradoxical and context-dependent. Early in
tumorigenesis TGF-β prevents tumor formation by supporting apoptosis and
inhibiting cell cycle progression. During late stages of tumor formation TGF-β
promotes invasion and immunosuppression (Landskron et al., 2014). Many cell
populations secrete TGF-β in the TME including the cancer cells, macrophages,
MDSCs, lymphocytes, fibroblasts and endothelial cells (Massagué, 2008). Overall,
TGF-β in the TME suppresses the development, proliferation, and function of antitumorigenic cells (Pickup, Novitskiy and Moses, 2013). Mice with defects in the
TGF-β signaling pathway develop benign neoplasia associated with inflammation
that eventually evolves to malignant tumors (Engle et al., 2002). The most notable
feature of TGF-β in the TME is to polarize macrophages towards M2 phenotype
(Gong et al., 2012). The suppression of TH1 response and T cell proliferation is
also mediated by TGF-β signaling (Gorelik, Constant and Flavell, 2002).
Transforming growth factor β inhibits the antitumor response of CTLs (Thomas and
Massagué, 2005) as well as impairs the maturation of NK (Marcoe et al., 2012)
and DCs, which otherwise would be able to detect cancer cells and initiate the
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tumor clearance process (Novitskiy et al., 2012). Lastly, TGF-β induces the
differentiation of naïve CD4+ cells into Treg, a very immunosuppressive subtype
that in addition to suppression of immune response also produces TGF-β (Chen
et al., 2003).
Chemokines constitute a subgroup of cytokines responsible for the recruitment
of immune cells along the concentration gradient of a ligand, a process known as
chemotaxis. Chemokine receptors belong to the G-protein coupled receptor
(GPCR) family of receptors and bind to more than one type chemokine ligand.
Chemokines are divided into four groups (CXC, CC, C, CX3C) determined by the
position of the first two cysteine residues in their protein sequence (Balkwill, 2004).
The trafficking of immune cells to the TME is mediated by combinations of different
chemokines. Hence, chemokines are considered important regulators of antitumor immunity and immune detection escape (Amedei, Prisco and M. D’Elios,
2013). Tumor-inhibitory cells CTLs, NK and T H1 cells express the chemokine
receptor CXCR3 and are intensively recruited to the TME in response to
chemokine ligands CXCL9, CXCL10, and CXCL11 (Nagarsheth, Wicha and Zou,
2017). The DCs expressing CCR6 migrate to the TME in response to CCL20
produced by tumor cells (Bell et al., 1999). Recruitment of macrophages to tumors
is mainly governed by CCR2-CCL2 (Qian et al., 2011) and CCR5-CCL5
chemokine axes (Azenshtein et al., 2002). Regulatory T cells expressing CCR4
are recruited to the TME by CCL22 derived from tumor cells and macrophages
(Curiel et al., 2004). The main chemokines attracting M-MDSCs to the tumors are
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CCL2 and CCL5. PMN-MDSCs rely on chemokines CXCL5, CXCL6 and CXCL8
to find their way to the TME (Kumar et al., 2016).
Recently, immunotherapy approaches targeting only a single chemokine axis
have failed to produce satisfactory results in patients with chronic inflammatory
diseases. The therapeutic failure probably happened as a result of the pleiotropic
effect of chemokines. In the context of cancer, targeting a specific chemokine axis
is most certainly affecting different population of cells in the TME. Thus,
combinatorial strategies aiming to simultaneously stimulate anti-tumor and silence
pro-tumor chemokines axes could potentially achieve meaningful results
(Nagarsheth, Wicha and Zou, 2017).
Melanoma Microenvironment
The strong interaction between tumorigenic cells and all other cell types in the
TME sustain melanoma development (Passarelli et al., 2017). At normal conditions
the proliferation of melanocytes is firmly regulated by keratinocytes through the
expression of adhesion molecules. During tumorigenesis melanoma cells
circumvent the microenvironmental regulation of proliferation by downregulating Ecadherin and overexpressing N-cadherin. The expression of N-cadherin also
mediates the interaction of melanoma cells with fibroblasts and endothelial cells in
the TME (Villanueva and Herlyn, 2008). A paracrine loop relying on growth factors
supports the proliferation of both melanoma cells and fibroblasts in the TME.
Melanoma cells secrete platelet-derived growth factor (PDGF) and fibroblast
growth factor (FGF) that stimulate fibroblasts to proliferate and to secrete growth
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factors insulin-like growth factor 1 (IGF-1) and HGF, further supporting melanoma
cell proliferation (Melnikova and Bar-Eli, 2009).
Melanoma has long been recognized as one of the most immunogenic types
of tumor, having the capacity to elicit strong anti-tumor responses (Passarelli et
al., 2017). Melanoma associated antigens such as melan-a, gp100, and tyrosinase
can be detected by T cells and trigger tumor-specific immune responses (Castelli
et al., 2000). The UV-induced high somatic mutation burden in melanoma creates
TAA that can be detected by immune cells (Wang et al., 2017). As such,
melanomas with high mutation load have good response to immunotherapies
(Ejeta et al., 2015). Recent findings have suggested that melanoma arises in a
chronic inflammatory environment (Umansky and Sevko, 2012). Oncogenic
signals are important not only for tumor cells’ deregulated proliferation but also for
creating an inflammatory milieu. Forced expression of BRAFV600E in normal
melanocytes results in the production of IL-1 and IL-6 (Kuilman et al., 2008).
Expression of pro-inflammatory cytokines IL-1, IL-6, and TNF-α are upregulated
when nevi are compared to thick primary melanomas (Moretti et al., 1999).
Additionally, melanoma cells express a variety of chemokines ligands including
CCL2, CCL5, CXCL1-3, CXCL5-8, and CXCL10 that recruit different populations
of immune cells to the TME (Richmond, Yang and Su, 2009).
Although remarkably immunogenic, melanoma develops a variety of strategies
to circumvent immune detection. Melanoma cells downregulate MHC-I molecules
impairing cytotoxic T cell activity (Ferrone and Marincola, 1995). Melanoma cells

30

do not display the ligands for NK cell activating receptors on their surface, allowing
them to escape NK destruction (Fuertes et al., 2008). Melanoma cells express PDL1, the ligand to the immune checkpoint PD-1, suppressing melanoma-specific
CTLs (Yang et al., 2008). The expression level of PD-L1 in melanoma tumors is
positively correlated with aggressiveness (Hino et al., 2010). The melanoma
genotype is also associated with the impairment of anti-tumor immune response
in the TME (Binnewies et al., 2018). In addition to inflammatory cytokines,
BRAFV600E

expression

in

melanoma

cells

drives

the

production

of

immunosuppressive cytokine IL-10 contributing to the evasion of immune
detection (Sumimoto et al., 2006). Melanocytic expression of BRAFV600E and βcatenin coupled with Pten deletion in a mouse model generated aggressive
melanomas that were poorly infiltrated by CTLs because of the lack of DCs in the
TME. The expression of β-catenin in melanoma cells reduces the availability of
CCL4 chemokines, which in turn diminishes the trafficking of DCs to the
microenvironment (Spranger, Bao and Gajewski, 2015).
Undoubtedly, immune cells are central players of immunosuppression in the
melanoma microenvironment. The seminal work by Tirosh and colleagues
expanded our understanding about the immune cells in the melanoma TME. The
authors performed single-cell RNA sequencing (RNA-Seq) of 4645 malignant and
non-malignant cells from 19 patients with metastatic melanoma to establish the
profile of stromal cells in the melanoma TME. They showed that the melanoma
ecosystem is consisted mainly of T (CD8+, CD4+ and Treg) and B lymphocytes. In
addition, there are other immune populations, namely macrophages and NK cells
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and stromal cells including CAFs and endothelial cells. In the T cell infiltrate of
metastatic melanomas, CTLs express cytotoxic genes together with exhaustion
markers PD-1 and CTLA-4. Furthermore, clonal expanded CTLs show signs of
exhaustion indicating the suppression of immune surveillance. Tregs represent a
small population of lymphocytes (57 out of 2068 cells) in TME. These
immunosuppressive cells overexpress immune checkpoint CTLA-4 and have a
moderate to low expression of cytotoxic marker GZB (Tirosh et al., 2016).
Transforming growth factor β is central to the Tregs mediated immunosuppression
in the melanoma TME. In addition to inhibiting cytotoxic T cell functions and APCs,
TGF-β also promotes Treg proliferation (Braeuer et al., 2014). Accordingly, these
data strongly suggest that melanoma is a type of “cold” tumor, thus in the
melanoma TME there are few activated CTLs and many immunosuppressive cells
preventing anti-tumor cytotoxic activity (Binnewies et al., 2018).
The intense research on melanoma microenvironment has paved the way for
the development of immunotherapies that have recently revolutionized the
management of melanoma disease producing long-lasting successful responses
(Giavina-Bianchi, Giavina-Bianchi Junior and Festa Neto, 2017). Melanoma
immunotherapy has been particularly focused on the employment of immune
checkpoint inhibitors anti-CTLA-4 and anti-PD-1, in order to rescue activation and
function of tumor-specific lymphocytes, respectively (Binnewies et al., 2018).
Cytotoxic T lymphocyte associated protein 4 (CTLA-4) is an inhibitory molecule
expressed by activated T cells that competes with co-stimulatory receptor CD28
for the B7 ligand expressed on the surface of DCs. CTLA-4 normally works as a
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molecular brake during the priming of T cells preventing excessive T cell
responses (Postow, Callahan and Wolchok, 2015). Preclinical studies blocking
CTLA-4 generated effective response against tumors (Leach, Krummel and
Allison, 1996) and encouraged the development of clinical trials using human
CTLA-4 blocking antibody (ipilimumab). Although preliminary studies had shown
that ipilimumab might have an initial delayed response associated with disease
progression (Saenger and Wolchok, 2008), CTLA-4 blockage in patients with
metastatic melanoma have produced an astonishing durable response for up to a
decade (Schadendorf, Hodi, et al., 2015). Ipilimumab was found to be more
effective than conventional chemotherapy in the treatment of patients with
advanced melanomas (Robert et al., 2011).
Targeting the PD-1 pathway using nivolumab or pembrolizumab blocking
antibodies is another very effective immunotherapy approach that has achieved
long-term satisfactory results in patients with metastatic melanoma (Topalian et
al., 2014). Programed cell death-1 (PD-1) is a negative regulator expressed by
exhausted CTLs during chronic immune response in the TME. Binding of PD-L1
expressed on the surface of tumor cells to the PD-1 receptor present in CTLs
inactivates immune responses against tumors (Ribas and Wolchok, 2018). A
possible explanation for the successful blockage of PD-1 pathway is the presence
of infiltrated tumor-specific CTLs in the TME (Haanen, 2017). An effective strategy
to convert “cold” melanomas into highly inflamed tumors is through intratumoral
injection of oncolytic virus. This procedure induced CTLs infiltration into the TME
and, after the treatment with pembrolizumab, resulted in reduction of tumor burden
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in more than 60% of patients with metastatic melanoma (Ribas et al., 2017). The
immune checkpoints CTLA-4 and PD-1 have temporal and spatial distinct
mechanisms of action. Cytotoxic T lymphocyte associated protein 4 regulates the
initial steps of immune response in the draining lymph node whereas PD-1 controls
the effector phase of immune response in the TME. These observations suggest
that combination of CTLA-4 and PD-1 immune checkpoints inhibitors would have
synergetic effects in the immune response against tumors (Postow, Callahan and
Wolchok, 2015; Ribas and Wolchok, 2018). In fact, melanoma patients treated with
pembrolizumab in combination with ipilimumab presented considerable longer
durable response rate when compared to monotherapy (Larkin et al., 2015).
In the last few years, a great body of data have shown that the gut microbiota
is an important modulator of melanoma response to immunotherapy and can be
manipulated to provide better clinical responses (Vancheswaran Gopalakrishnan
et al., 2018). Anti-CTLA-4 treatment changed the diversity of microbiota in mice,
specifically decreasing the amount of Bacteroidales and increasing Clostridiales
load in the gut. Germ-free mice treated with anti-CTLA-4 did not exhibit anti-tumor
response, which was reestablished when mice received immune checkpoint
inhibitor in combination with Bacteroidales isolates. Furthermore, fecal microbiota
transplantation (FMT) from melanoma patients with high amounts of Bacteroidales
enhanced the anti-tumor effect of CTLA-4 blockage in mice (Vetizou et al., 2015).
Interestingly, mice from different vendors but with the same genetic background
responded differently to PD-1 pathway blockage. The determinant of the distinct
response was the amount of Bifidobacterium in the microbiota. Mice with more
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Bifidobacterium in the gut showed delayed melanoma growth when treated with
anti-PDL-1. When mice with low amounts of Bifidobacterium were treated with
these bacteria they presented improved anti-tumor response to PD-L1 blockage.
Bifidobacterium positively influences DCs function and consequently improves
anti-tumor activity of CTLs (Sivan et al., 2015). Recently, these findings were
shown to have clinical relevance for patients with metastatic melanoma (Jobin,
2018). As observed in the preclinical studies, melanoma patients responding (R)
to PD-1 blockage had distinct microbiota profile compared to those not responding
(NR) to treatment. Favorable microbiota augmented the number of APCs and
CTLs in the TME as well as the frequency of CTLs compared to Tregs. Mouse
models validated these observations and confirmed that FMT from R melanoma
patients to germ-free mice was able to improve anti-tumor response to anti-PD-1
treatment (Matson et al., 2018; V. Gopalakrishnan et al., 2018).
1.3.

Endothelin

Endothelin (Edn) is a cytokine ubiquitously expressed in various organs and
has remarkable pleiotropic functions. There are 3 isoforms of endothelins - Edn1,
Edn2, and Edn3 - that bind to 2 different GPCRs, endothelin receptor type A
(Ednra) and type B (Ednrb). Endothelin 1 is the predominant and more relevant
isoform and binds with the same affinity to both Ednra and Ednrb. Edn2 also has
similar affinity to Ednra and Ednrb whereas Edn3 is very selective for Ednrb
(Aubert and Juillerat-Jeanneret, 2016). Binding of endothelin to one of its cognate
receptors triggers the stimulation of a variety of downstream effectors (Rosanò,
Spinella and Bagnato, 2013). Activation of endothelin receptor initiates PLCβ
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signaling pathway resulting in PKC activation (Simonson and Dunn, 1990).
Endothelin receptors activate MAPK and PI3K pathways leading to ERK
phosphorylation (Iwata et al., 2009) and mTOR activation (Wu et al., 2012).
Different

cell

types

secrete

endothelins

including

endothelial

cells,

cardiomyocytes, leukocytes, glial cells and epithelial cells in the lung and kidney.
Equally diverse is the roster of cell populations that express receptors to endothelin
and includes among others, endothelial and smooth cells, neurons, hepatocytes,
adipocytes, keratinocytes, and melanocytes (Khimji and Rockey, 2010). Of note,
the expression pattern of each endothelin varies regarding organs and cell types
(Masaki, 2004).
Endothelin Physiology and Pathology
Endothelins were first discovered as mediators of vascular function
(Yanagisawa et al., 1988). Endothelial cells secrete Edn1 that binds to the Ednra
expressed on smooth cells and trigger vasoconstriction. Endothelin 1 is considered
to be the most potent vasoconstrictor already described. Endothelin 1 derived from
endothelial cells can also bind to Ednrb expressed by neighboring endothelial cells.
Stimulation of Ednrb in endothelial cells induces the secretion of nitric oxide (NO),
a strong vasodilator for smooth cells (Kawanabe and Nauli, 2011). Endothelins
have many other physiological functions besides vasoconstriction. For example,
endothelins regulate development of neural crest cells (Kedzierski and
Yanagisawa, 2001) bronchoconstriction in the lungs (Uchida et al., 1988) and
water and salt excretion in the kidneys (Kohan, 2006). Shortly after endothelin
discovery, a variety of pathological conditions were found to be associated with
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alterations

in

hypertension

endothelin
and

physiology.

atherosclerosis,

Cardiovascular

pulmonary

arterial

diseases

including

hypertension

and

glomerulosclerosis are all diseases that have an inflammatory component
associated with deregulation in endothelin signaling suggesting that endothelin
modulates immune system functions (Barton and Yanagisawa, 2008).
The inflammatory process involves changes in the vascular permeability and
trafficking of leukocytes to the sites of tissue injury. Endothelin is associated with
these events and therefore, is considered a pro-inflammatory cytokine (Figure 1.7)
(Nett et al., 2006). The transcription factor NF-κB, a central regulator of
inflammation, is under the control of endothelin signaling (Wilson, Simari and
Lerman, 2001). Endothelin increases local vascular permeability (Filep et al., 1992)
and stimulates the expression of adhesion molecules (i.e., ICAM-1) on endothelial
cells (Hayasaki et al., 1996), allowing the infiltration of leukocytes into the
inflammation site. Endothelin in the inflammatory milieu stimulates neutrophil
accumulation (López Farré et al., 1993) and is a chemoattractant for monocytes
(Hanggono Achmad and Rao, 1992), and macrophages. Of note, the chemical
structure of mature endothelins resembles that of some chemokines (Grimshaw,
Wilson and Balkwill, 2002). Secretion of pro-inflammatory cytokines IL-1, IL-6,
TNF-α, and IFN-γ is regulated by endothelin expression (Yang et al., 2004).
Interestingly, activated T cells produce TNF-α and IFN-γ inducing monocytes to
secrete endothelin, which in turn enhances the inflammatory process (Shinagawa
et al., 2017). In addition to endothelial cells and monocytes, DCs (Guruli et al.,
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2004) and macrophages (Ehrenreich et al., 1990) are other sources of endothelin
in the inflammatory environment.
Endothelin signaling in melanocytes and melanoma cells
Many cytokines are associated with melanocyte and melanoma biology, among
them are the endothelins. The Edn3/Ednrb pathway has been implicated in
melanocyte development as well as melanoma progression (Saldana-Caboverde
and Kos, 2010). Endothelin 3 regulates the proliferation and survival of melanocyte
precursors (Lahav et al., 1996, 1998) and promotes melanoblast differentiation into
melanocytes (Reid et al., 1996). The essential role of endothelin signaling during
melanocyte development is demonstrated by mouse models with spontaneous
mutations in Edn3 (Baynash et al., 1994) and Ednrb genes (Hosoda et al., 1994).
These mice have hypopigmented phenotypes because of the reduction in the
number of melanoblasts and impaired migration of melanocyte precursors during
development (Pavan and Tilghman, 1994; Lee, Levorse and Shin, 2003).
Conversely, overexpression of Edn3 in the mouse skin leads to an augmented
melanoblast population and a hyperpigmented phenotype (Garcia et al., 2008).
The communication between keratinocytes and melanocytes is mediated by
endothelin. Upon UV light exposure, keratinocytes release Edn1 (Imokawas, Yada
and Miyagishi, 1992) that stimulates melanin production in the melanocytes
(Imokawa et al., 1997). Thus, endothelin may have an indirect protective effect
against melanoma initiation (Saldana-Caboverde and Kos, 2010).
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Initially, EDNRB was thought to be expressed at low levels in melanoma cells.
Profiling of a cDNA library detected the downregulation of EDNRB in 16 out of 17
human melanoma cells lines (Eberle et al., 1999). Analysis of primary and
metastatic melanoma cell lines reported that EDNRB is downregulated when
metastatic cells are compared to primary melanoma (Kikuchi et al., 1996). Further
studies including human samples challenged the in vitro findings and showed that
EDNRB expression increases during melanoma progression. A gene profiling
study of melanoma cell lines and tumor biopsies showed that EDNRB is
overexpressed in most of human melanomas (Bittner et al., 2000). Demunter et al.
(2001) demonstrated that EDNRB expression gradually increases from benign
nevi to metastatic melanoma and proposed ENDRB as marker for melanoma
progression (Demunter et al., 2001). Tang et al. (2008) were the first to address
the role of EDN3 on melanoma progression. The analysis of biopsies and cell lines
revealed that metastatic melanoma cells express high levels of EDN3 suggesting
that its autocrine secretion might modulate melanoma metastasis (Tang et al.,
2008). Using human samples and a mouse model of melanoma brain metastasis,
Cruz-Munoz et al. (2012) showed that the overexpression of EDNRB promotes
melanoma metastatic growth within the central nervous system (CNS) (CruzMuñoz et al., 2012). The proliferation of metastatic melanoma cells in the brain
might take place as a result of EDNRB interaction with EDN3 since this ligand is
abundant in the CNS (Davenport et al., 2016). Additional studies demonstrated
that Ednrb activation triggers many molecular events relevant for melanoma
metastasis. Binding of EDN1 or EDN3 to EDNRB downregulates E-cadherin
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(Jamal and Schneider, 2002) and increases the expression of N-cadherin and as
well as secretion of MMPs. Endothelin Receptor B activation also stimulates
proliferation, migration, and invasion of melanoma cells (Bagnato et al., 2004).
Altogether, these findings strongly suggest that the Ednrb/Edn3 axis contributes
significantly to melanoma progression. Figure 1.8 summarizes the effects of
endothelin signaling in melanoma cells.
As discussed above a well-established body of data establishes that EDNRB
plays tumor-promoting roles during melanoma development. Conversely, few
studies have addressed the tumor suppressive aspects of EDNRB. These reports
suggest that, in some specific contexts, EDNRB can act as a tumor suppressor
gene preventing melanoma initiation. In the RET transgenic mouse model of
melanoma, Ednrb expression is reduced when malignant tumors are compared to
benign melanocytic lesions. Furthermore, RET transgenic mice carrying a
heterozygous deletion of Ednrb (Ednrb+/-; RET-mouse) develops de novo
melanomas that are more prone to metastasize to the lungs compared to RETmouse (Kumasaka et al., 2010). Additional studies using the same mouse model
revealed that the reduction of Ednrb levels is associated with Plexin
downregulation. Plexin is considered a melanoma tumor suppressor (Scott et al.,
2009) and the positive correlation between Ednrb and Plexin expression supports
a possible tumor suppressive role of Ednrb (Kumasaka et al., 2015). Variants in
the EDNRB gene might underscore the tumor suppressive effect of EDNRB.
Berger et al. (2006) demonstrated that EDN1 had reduced binding to an EDNRB
variant found in a human melanoma cell line. This EDNRB variant is probably
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defective in the N- and C- terminal domains making the receptor unable to bind to
endothelins (Berger, Bernasconi and Juillerat-Jeanneret, 2006).
The relevance of EDNRB variants for melanoma incidence is still under debate.
Caucasians harboring the germline variant S305N in the EDNRB gene are
associated with increased predisposition to melanoma (Soufir et al., 2005).
However, two case-control studies, one in Germany (Thirumaran et al., 2006) and
another in Spain (Fernandez et al., 2009) claimed that S305N variant is not
associated with melanoma risk. The Spanish study took in consideration only
sporadic melanoma cases. Still, some reports have linked EDNRB mutation with
familial melanoma. A study with 2 independent large populations of Caucasians
showed that S305N variant in EDNRB gene is not linked with sporadic melanoma
but is significantly associated with CDKN2A mutations, which is responsible for
familial melanoma. Therefore EDNRB variants might be important players of
inheritably susceptibility to melanoma (Spica et al., 2011).
EDNRB and melanoma: clinical opportunities
Notwithstanding the recent advances regarding targeted therapy and
immunotherapy, melanoma treatment still faces many challenges. Clinical
targeting of EDNRB emerges as a very promising approach despite the
paradoxical findings. The most explored strategy is to block EDNRB using
bosentan, a dual antagonist to EDNRA/EDNRB, or antagonist selective for EDNRB
such as BQ788, A-192621. Some of these inhibitors are routinely employed for
treating cardiovascular or pulmonary dysfunctions and their therapeutic features
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have been assessed in the context of melanoma (Aubert and Juillerat-Jeanneret,
2016). Most of the data exploring blockage of endothelin signaling in melanoma
came from studies using cell lines and preclinical mouse models (Lahav, Heffner
and Patterson, 1999; Rosanò et al., 2004; Smith et al., 2017). Clinical trials aiming
to block EDNRB in patients with melanoma demonstrated limited beneficial results
and therefore might require additional investigation (Kefford et al., 2007; Wouters
et al., 2015).
The endothelin receptor inhibitor BQ-788 very efficiently competes with EDN1
for EDNRB, but not EDNRA, and is considered the strongest EDNRB antagonist
(Ishikawa et al., 1994). Melanoma cell lines exposed to BQ-788 showed cell growth
inhibition as well as enhanced cell death. The same effects were not observed
when melanoma cells are treated with EDNRA selective inhibitor. Furthermore,
BQ788 treatment abrogated tumor growth in melanoma xenografts (Lahav,
Heffner and Patterson, 1999). The apoptotic effect of BQ-788 was more prominent
in aggressive melanoma cells and relied on the reduction of survival factor BCL2A1
expression associated with caspase-6 activation (Lahav et al., 2004). Bagnato and
colleagues extensively explored the role of EDNRB blockage in melanoma. They
showed that BQ-788 impairs the phosphorylation of ERK and decreases
melanoma cell proliferation. BQ788 treatment also prevents upregulation of Ncadherin, downregulation of E-cadherin as well as secretion of metalloproteinases
(Bagnato et al., 2004).

42

Modifications on the chemical structure of EDNRA antagonists led to the
development of the oral non-peptide selective EDNRB antagonist A192621 (von
Geldern et al., 1999). Administration of A192621 to melanoma xenografts had
remarkable tumor suppressor effects. The EDNRB antagonist A192621 abolished
tumor cell proliferation as well as reduced tumor volume in nude mice (Bagnato et
al., 2004; Spinella et al., 2007). Melanoma brain metastatic cell lines exhibited
decreased cell proliferation when treated with A192621. Monotherapy with
A192621 is infective in brain metastasis treatment because of the inability of
A192621 to cross the blood-brain barrier (BBB). However, when A192621
treatment was associated with inhibitors of efflux pump P-glycoprotein (PGP), the
EDNRB inhibitor was able to penetrate the CNS and decrease the size of
melanoma brain metastasis (Cruz-Muñoz et al., 2012).
Tumorigenesis is highly dependent on the process of angiogenesis.
Therapeutic inhibition of EDNRB has controversial effects in melanoma
angiogenesis. The treatment with BQ-788 was shown to play a pro-angiogenic
role. Melanoma cells treated with BQ-788 showed increased expression of VEGF
and hypoxia-inducible factor-1α (HIF1α) and downregulation of the angiogenic
suppressor gravin. It is possible that the increase expression of VEGF resulting
from EDNRB blockage encourages endothelial cells to proliferate (Lahav et al.,
2004). Patients treated with BQ-788 exhibited abundance of blood vessels and
increased expression of HIF1α. Although angiogenesis is helpful for melanomas
as it increases the blood supply, the formation of new blood vessels can also be
harmful to tumors since they create new routes for immune cells to be recruited to
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the TME (Wouters et al., 2015). Conversely, A192621 treatment seems to have
evident anti-angiogenic effect in melanoma. Melanoma xenografts treated with
A192621 presented increased PDH2 expression and downregulation of HIF1α,
this in turn impaired angiogenesis and tumor growth (Spinella et al., 2007, 2010).
Despite the successful anti-melanoma effect of EDNRB blockage in preclinical
studies, the clinical relevance of this approach is still elusive. Bosentan is a nonpeptide dual EDNRA and EDNRB antagonist. Preclinical studies showed that this
EDNRB inhibitor reduces cell viability and stimulates apoptosis in human
melanoma cells. The apoptotic effect of bosentan is enhanced when it is combined
with chemotherapy drug dacarbazine (DTIC) (Berger, Bernasconi and JuilleratJeanneret, 2006). These results encouraged clinical trials that addressed the antitumor effect of bosentan in patients with metastatic melanoma. A phase II clinical
study showed that 6 out 32 patients with stage IV melanoma presented disease
stabilization upon monotherapy with bosentan (Kefford et al., 2007). Unfortunately,
in a supplementary study, the combination of bosentan with DTIC showed no effect
in tumor progression and survival of patients with metastatic melanoma (Kefford
et al., 2010). One of the potential reasons for the unsuccessful outcomes of
EDNRB blockage in melanoma patients is the absence of previous screening for
patients with high levels of intratumoral EDNRB. Blocking EDNRB using BQ788
seems to be more effective for melanoma patients. A recent clinical study
demonstrated that intralesional administration of the selective EDNRB antagonist
directly reduced the expression of the proliferation marker Ki-67 as well as
diminished tumor growth. Treatment with BQ-788 also enhanced immune cell
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infiltration in melanoma, suggesting that future studies evaluating the efficacy of a
combination of EDNRB inhibitor and immune checkpoint inhibitors should be
carried out (Wouters et al., 2015).
To overcome the low sensitivity of small molecule antagonists such as BQ-788,
functional monoclonal antibodies (mAB) can also be used as therapeutic
strategies. Rendomab-B1 was the first described mAb with antagonist ability to the
human EDNRB. Rendomab-B1 exhibits dual pharmacological action, it competes
with EDN1 ligand as well as promotes EDNRB internalization (Allard et al., 2013).
Another approach that has been tested in melanoma is antibody-drug conjugated
(ADC) therapy that combines antibodies with potent cytotoxic agents. Asundi and
colleagues (2011) developed a monoclonal antibody (5E9) conjugated with the
potent cytotoxic compound MMAE. The ADC 5E9 has high affinity to EDNRB and
is rapidly internalized. Antibody-drug conjugated 5E9 shows remarkable anti-tumor
activity in both melanoma cell lines and xenograft models expressing EDNRB
(Asundi et al., 2011). Further studies assessed the combinatorial effect of antiEDNRB ADC with MAPK inhibitors. The exposure to MAPK inhibitors to cell lines
and tumor models harboring either wild type or mutant BRAF and NRAS promoted
expression of EDNRB, even in cells resistant to MAPK inhibitors. The increased
expression of EDNRB in turn enhanced the anti-tumor activity of the ADC. Taken
together, these data indicate that the combination of MAPK inhibitors with antiEDNRB ADC might be a powerful and effective approach in a broad range of
patients with melanoma (Asundi et al., 2014).
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A more recent study explored the role of endothelin during resistance to BRAFi.
Treatment with BRAFi increases MITF expression in melanoma cells, which is
heterogeneously maintained among tumors cells. When MITF high and MITFlow
melanoma cells were co-cultured in the presence of BRAFi, MITFhigh protected
MITFlow melanoma cells and stimulated their growth. The shielding effect was
maintained by EDN1 released from BRAFi resistant cells which protected
otherwise drug-sensitive melanoma cells and led to ERK re-activation via PCK and
CRAF pathways activation. Endothelin signaling also perturbates AXL high
melanoma cells since monotherapy with BRAFi increased AXL levels and
combination with endothelin blockage reduced AXL expression. These findings
suggest the endothelin signaling is an important regulator of melanoma resistance
to BRAFi (Smith et al., 2017).
Furthermore, endothelin coordinates the phenotypic heterogeneity that takes
place when tumors become resistant to BRAFi. The phenotypic heterogeneity is
demonstrated by the correlation between endothelin receptors and MITF/AXL
expression levels. Melanoma cells with MITFhigh phenotype have an increased
expression of EDNRB but reduced levels of EDNRA; in AXL high tumor cells this
correlation is inverted. Therefore, BRAFi treatment increases MITF expression
which in turn leads to EDN1 production. Endothelin 1 might have an autocrine
effect and binds to EDNRB in MITFhigh cells (or paracrine in other MITFhigh cells)
re-activating ERK and consequently regulating proliferation and survival.
Endothelin 1 might also act in a paracrine fashion in AXL high cells upregulating
EDNRA. In the paracrine context, endothelin signaling re-activates ERK but
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promotes only cell proliferation. In addition to interfering with the activation of
BRAF, combination of BRAFi with endothelin receptor blockage might also act in
the TME as endothelin in crucial for many stromal cells (Smith et al., 2017).
1.4.

Research Questions

Melanoma is one of the most immunogenic types of tumors and is also known
to grow in an immunosuppressive environment. The latter affords tumorigenic cells
with the ability to escape the immune system and ultimately progress and
metastasize. The Edn3/Ednrb pathway is considered a marker for melanoma
progression. Still, it is not clear whether melanoma cells themselves or other cells
present in the TME respond to endothelin signaling. Despite its many
demonstrated pro-tumorigenic functions, it is still uncertain if endothelin is
important for immune escape. Regulatory T cells are strong immunosuppressive
cells present in the TME that limit tumor-specific immune responses and promote
immune evasion as well as cancer progression. Currently there is no information
about Treg cells responding to endothelin signaling in melanoma. My central
hypothesis is that overexpression of Edn3 creates an immunosuppressive
environment promoting melanoma growth and progression. To test the
hypothesis, I will address the following questions:
Question 1: Does End3/Ednrb signaling promote melanoma progression?
I evaluated the role of Edn3 signaling in melanoma progression by injecting
relevant murine melanoma cell lines in an immunocompetent mouse model that
overexpresses Edn3 in the skin (K5-tTA;TRE-Edn3-lacZ which will be referred to

47

as K5-Edn3). I found that when Edn3 is overexpressed in the TME, tumors grow
significantly more and are more aggressive.
Question 2: Can tumorigenic and stromal cells respond to Edn3 in the
microenvironment?
To address this question I characterized Ednrb expression in different
population of immune cells present in the melanoma TME. I observed that Treg is
the only population in TME that has consistently different amounts when Edn3 is
overexpressed.
Question 3: Does End3/Ednrb signaling play immunosuppressive roles in the
melanoma TME?
I addressed the inhibitory effect of endothelin signaling during the immune
response against melanoma. I found that Endothelin was required for immune
escape of highly immunogenic melanoma cells. The immunosuppressive features
of Tregs were enhanced in presence of Edn3. Overexpression of Edn3 in the
melanoma microenvironment resulted in upregulation of immunosuppressive
cytokines and decreased levels of cytokines that elicit anti-tumor immunity.
Melanomas exposed to high levels of Edn3 were sensitive to immune checkpoint
inhibitor as well as to Ednrb blockage.
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1.5.

Figures

Figure 1.1 Melanoma progression pathways
The linear pathway of progression from melanocytes to non-CSD or CSD metastatic
melanomas involves the development of intermediate lesions through the acquirement
of a series of genetic alterations. Alternatively, during the parallel pathway the
development of melanocytic lesions may not require some precursor lesions to form
metastatic melanoma.
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Figure 1.2 Cells types and signaling molecules in the tumor microenvironment
(TME)
The different cell populations present in the tumor microenvironment and their
relationship is represented here. Cells from the tumor immune surveillance system can
detect nascent cancer cells and eliminate them. Immune suppressive cells impair the
mechanisms of immune surveillance which favor tumor progression. CAFs, endothelial
cells and other signaling molecules also support the tumor development.
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Figure 1.3 Macrophage polarization
Monocytes can be polarized towards M1 or M2 type of macrophages. The cytokine IFNγ polarizes monocytes towards M1 phenotype, which produces IL-1, IL-6, IL-12 and
TNF-α cytokines. M2 macrophages are induced by IL-10, TGF-β, IL-4 and IL-13
cytokines and produce anti-inflammatory cytokines.
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Figure 1.4 Naïve CD4+ T cell differentiation
Naïve CD4+ T cell differentiates into different effector subtypes depending on which
cytokines are available during antigen presentation by APCs. Each subtype has a
different biological role and is distinguished by its own cytokine profile.
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Figure 1.5 Tumor inhibitory cytokine network
A small number of cytokines are responsible for controlling tumor immune surveillance.
TH1 cells secrete IL-2 (which sustain the proliferation of cytotoxic cells) and IFN-γ, a
cytokine that polarizes macrophages towards M1 phenotype. M1 macrophages produce
IL-12 and pro-inflammatory cytokines IL-1, IL-6 and TNF-α that regulate anti-tumor
immunity.

53

Figure 1.6 Cellular targets of immunosuppressive cytokines
IL-10 and TGF-β are central modulators of immunosuppression in the TME. These
cytokines inhibit the anti-tumor activity of NK cells, T H1, CTL, DC and M1 cells and
activate Treg cells.
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Figure 1.7 Endothelin and inflammation
Endothelin regulates important events that happen during inflammation. Endothelin
increases vascular permeability and the expression of adhesion molecules in blood
vessels. Endothelin also recruits leukocytes and stimulates the secretion of proinflammatory cytokines. Endothelial cells, macrophages, DCs and monocytes are some
of the cell populations that supply the inflammatory milieu with endothelin.
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Figure 1.8 Endothelin signaling activation in melanoma cells
The activation of Edn3/Ednrb axis in melanoma cells triggers many cellular mechanisms
that promote melanoma progression.
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CHAPTER
2. Expression of Ednrb in Melanoma Microenvironment
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2.1.

Introduction

Expression of endothelins and their cognate receptors have been detected in
a variety of tumor types (Nelson et al., 2003). Colon (Egidy, Juillerat-Jeanneret, et
al., 2000), lung (Giaid et al., 1990), bladder (Said et al., 2011), prostate (Gohji et
al., 2001) ovarian (Rosanò, Spinella and Bagnato, 2010) and breast (Grimshaw,
2005) cancers are examples of carcinomas that express components of the
endothelin signaling pathway. Glioblastoma (Egidy, Eberl, et al., 2000) and
melanoma (Demunter et al., 2001) are non-carcinomas that also express
endothelin. As previously discussed in Chapter 1, it has been clearly demonstrated
that tumor cells express endothelin. It is has also become evident that endothelin
is not only expressed by tumor cells but also by multiple populations of stromal
cells in the TME including fibroblasts, endothelial and immune cells (Rosanò,
Spinella and Bagnato, 2013; Rosanò and Bagnato, 2016). It is also widely
accepted that stromal cells in the TME are major players during tumor
development. Based on these findings endothelin has been proposed as an
important modulator of tumor-stromal cells interactions in the TME (Binder et al.,
2009).
Very interestingly, the expression pattern of endothelins and their cognate
receptors in the TME is different when epithelial and non-epithelial tumors are
compared. In carcinomas, the main source of endothelin ligands in the TME is
usually the tumor cells themselves. With respect to the receptors, there is some
variability in that Ednra is mostly expressed by cancer cells such as in prostate,
ovarian and breast cancer whereas the expression of Ednra is generally detected
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in other cells inside the TME such as in glioblastoma (Aubert and JuilleratJeanneret, 2016).
The non-carcinoma type of cancer for which the endothelin pathway has been
best characterized is glioblastoma. In glioblastoma, stromal cells express Ednra
and are the main source of endothelin while tumors cells express Ednrb (Egidy,
Eberl, et al., 2000). Although melanoma is considered a non-carcinoma type of
tumor, it may also share some features with carcinomas because melanocytes
originate from ectodermal-derived neural crest cells (Braeuer et al., 2014).
Melanoma cells express EDNRB (Yohn et al., 1994; Lahav, Heffner and Patterson,
1999; Bagnato et al., 2004; Asundi et al., 2011) as well as secrete EDN1 (Chiriboga
et al., 2016) and EDN3 (Tang et al., 2008).It is not clear whether stromal cells
respond to the endothelin available in the melanoma microenvironment. Recently,
Chiriboga and colleagues detected the expression of EDN1 in macrophages found
in melanoma tumors. Yet, the authors did not address the expression of endothelin
receptors in stromal cells (Chiriboga et al., 2016).
Regardless of the embryonic origin of cancer cells, endothelin signaling plays
diverse roles in the TME (Figure 2.1). In the TME, the endothelin pathway has
been mostly evaluated in fibroblasts and endothelial cells. Endothelin participates
in a bidirectional stimulatory loop involving breast cancer cells and fibroblasts in
the TME. Tumor cells secrete EDN1 that stimulates the production of inflammatory
mediator PGE2 in fibroblasts. In presence of pro-inflammatory cytokine IL-1, PGE 2
induces EDN1 production in tumor cells (Patel, Sheth and Schrey, 1997).
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Endothelin signaling mediates the conversion of quiescent fibroblasts into cancerassociated fibroblasts (CAFs) in colon cancer, which is crucial for the creation of
the permissive stroma for tumor cells. In vitro activation of each endothelin receptor
produces different outcomes in CAFs and blockage of endothelin receptors
prevents CAFs activity. Activation of EDNRA promotes cell growth while EDNRB
stimulation is responsible for CAFs migration. Both EDNRA and EDNRB regulates
CAFs contraction. Additionally, EDN1 induces the expression of profibrotic genes,
secretion of ECM components and MMP-2 (Knowles et al., 2012).
The connection between endothelin and endothelial cells in the TME has been
addressed in many studies. Endothelin directly and indirectly promotes
angiogenesis in the TME. EDNRB activation by EDN1 promotes endothelial cell
proliferation, migration, and invasion (Salani, Taraboletti, et al., 2000). Biding of
EDN1 on EDNRA expressed by tumor cells results in the secretion of VEGF, the
master regulator of angiogenesis (Salani, Castro, et al., 2000). Activation of
endothelin signaling in blood vessels functions as an important regulator of
immune cell recruitment to the TME. In fact, EDNRA and EDNRB show contrasting
effects in the recruitment of tumor-specific lymphocytes. Overexpression of
EDNRB in endothelial cells from aggressive glioblastomas and ovarian cancer is
associated with less cytotoxic T lymphocytes (CTLs) infiltration (Buckanovich et
al., 2008) and more regulatory T cells (Tregs) present in the TME. These data
suggest that high expression of EDNRB in TME cells impairs recruitment of tumor
inhibitory immune cells while contributing to evasion of immune detection
(Nakashima et al., 2016). EDNRB blockage increases the expression of adhesion
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molecules ICAM-1 in the vasculature, which in turn enhances lymphocytes homing
to the TME (Buckanovich et al., 2008). Ovarian tumors treated with dual
EDNRA/EDNRB inhibitor showed an unexpected decrease in ICAM-1 expression
and consequently a reduced amount of CD8+ infiltrate. This finding implicates that
EDNRA activation is essential for anti-tumor cells recruitment while stimulation of
EDNRB prevents CTL mediated responses against tumors (Coffman et al., 2013).
Accordingly, EDNRB blockage alone might be more beneficial to patients than
simultaneous inhibition of EDNRA and EDNRB.
Endothelin is considered a chemoattractant for macrophages to the TME.
EDN1 produced by bladder cancer cells promotes macrophage recruitment via
chemokine CCL2 production (Said et al., 2011). Beyond chemotaxis, endothelin
also increases the expression of genes associated with macrophage activation
(Grimshaw, Wilson and Balkwill, 2002). Tumor-derived EDN1 stimulates EDNRA
activation in tumor-associated macrophages (TAMs) resulting in production of proinflammatory cytokines TNF-α, IL-6 and COX-2 (Said et al., 2011).TAMs also
induce activation of endothelin signaling in endothelial and breast cancer cells.
This activation promotes the expression of adhesion molecules resulting in cancerendothelial cell adhesion and transendothelial migration (Chen et al., 2014).
Dendritic cell (DC) is another type of antigen presenting cell (APC) of which
function is regulated by endothelin signaling. Remarkably, each endothelin
receptor impacts DCs function in opposite manners. EDNRA expression in human
DCs increases the expression of activation markers, enhancing DCs capability to
activate T cells. EDNRA consequently mediates antigen presentation features of
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DCs. DCs expressing EDNRA secrete immunomodulatory cytokine IL-12 and
show reduced apoptosis. In contrast, expression of EDNRB by DCs decreases
their maturation and survival suggesting that EDNRB suppresses immune
response (Guruli et al., 2004).
Several studies using tumor types other than melanoma have explored the
microenvironmental role of endothelin signaling. Edn3/Ednrb is considered a
marker for melanoma progression. EDN3 (Tang et al., 2008) as well as EDNRB
(Demunter et al., 2001) expression has been detected in melanoma patients. Still,
the exact cellular type expressing the receptor in the TME has not been
determined. The present study investigated the microenvironmental expression of
Ednrb in mouse and human melanomas.
2.2.

Results

To better understand the role of endothelin signaling in the melanoma
microenvironment green fluorescent protein (GFP) labeled YUMM1.7 and B16F10
murine melanoma cells were subcutaneously and intradermally injected in wildtype and K5-tTA; TRE-Edn3-lacZ (K5-Edn3, for simplicity) transgenic mice. The
K5-Edn3 mouse model was developed in our laboratory and overexpresses Edn3
in the skin. In this system, the overexpression of Edn3 is under the control of the
keratin 5 promoter. Due to the abundance of Edn3 in the skin, melanocytes are
maintained in the dermal/epidermal junction, mimicking their location in human
skin (Garcia et al., 2008). The aberrant expression of Edn3 in the skin of K5-Edn3
mice is shown in Figure 2.2A.
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Human melanoma initiation and development are mainly driven by activation
of oncogenic protein BRAFV600E as well as deletion of PTEN and CDKN2A genes
(Shain and Bastian, 2016). These genetic alterations have recently been modeled
in the YUMM1.7 mouse cell line (Meeth et al., 2016). YUMM1.7 cells were derived
from BRafV600E/+;Pten-/-; Cdkn2a-/- transgenic mice (Scortegagna et al., 2014).
Consequently, these cells carry mutations commonly found in human melanomas.
Since YUMM1.7 cells are not pigmented they were labeled with GFP to facilitate
the detection of metastatic cells. Figure 2.2B illustrates the protocol used to
generate the YUMM1.7-GFP melanoma cells. B16F10 melanoma cells were
derived from a spontaneous murine tumor in the early 1970’s (Fidler, 1973) and
are still extensively employed in cancer research due to its highly aggressive
features. B16F10-GFP cells were injected in both K5-Edn3 and wild-type mice to
test the environmental role of Edn3 in a widely used melanoma model.
Endothelin increases tumor aggressiveness
YUMM1.7-GFP melanoma cells generated detectable tumors 7 days after
subcutaneous injection. Both wild-type and K5-Edn3 tumors had similar growth
rates during the following 7 days. Seventeen days after injection the subcutaneous
tumors in K5-Edn3 mice started to grow faster than wild-type. K5-Edn3 and wild
type tumors had an average volume of 1054 mm3 and 673 mm3, respectively. K5Edn3 tumors continued to grow faster for the next days. Twenty-one days after
injection K5-Edn3 tumors were significantly larger (p<0.05) than wild-type tumors
(Figure 2.3A). Once tumors reached a volume close to 2 cm 3 the mice were
euthanized. Autopsy did not reveal any visible metastasis although cross84

sectioning of lungs showed the presence of GFP + cells in the lungs of one K5Edn3 mouse (Figure 2.3B). Since Edn3 overexpression in the K5-Edn3 mice is
restricted to the skin, YUMM1.7-GFP cells were intradermally injected in the mice
to ensure that melanoma cells were exposed to an Edn3-rich environment.
Intradermal injection of YUMM1.7-GFP cells showed similar results to those
observed upon subcutaneous injection. Intradermal YUMM1.7-GFP tumors
generated in K5-Edn3 mice were approximately two times larger than in wild-type
mice (p<0.05) (Figure 2.4A) and lung metastases (n=1) was detected only when
the primary tumors were exposed to abundant Edn3 (Figure 2.4B).
In order to validate the observations made using YUMM1.7-GFP cells, B16F10GFP melanoma cells were injected in both wild-type and K5-Edn3 mice. Similar to
YUMM1.7-GFP, intradermal B16F10-GFP tumors were more aggressive when
growing in presence of Edn3. Tumors generated in K5-Edn3 mice were six times
larger than in wild-type mice (p<0.05) (Figure 2.5A) and only K5-Edn3 tumor (n=1)
metastasized to the lungs (Figure 2.5B). These results indicate that Edn3 is
responsible for melanoma growth and corroborates previous reports claiming that
endothelin is considered a marker for melanoma progression.
Melanoma cells express Ednrb
Given the effect of overexpression of Edn3 on YUMM1.7-GFP tumors, I asked
whether tumor cells express Ednrb and therefore are capable to respond to Edn3
present in the microenvironment. EDNRB expression has already been
demonstrated in human melanoma cell lines. Immunofluorescence staining for
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GFP and Ednrb detected GFP+ melanoma cells expressing Ednrb in both wild-type
and K5-Edn3 tumors (Figure 2.6A, white arrows). The antibody against GFP was
used in order to amplify the signal for immunostaining. The visual inspection of four
sections per tumor from YUMM1.7-GFP tumors (n=5/group) showed that very few
melanoma cells expressed Ednrb.
In an effort to quantify Ednrb+/GFP+ melanoma cells, tumors were dissociated
and analyzed using flow cytometry. A small population of GFP + melanoma cells
that expressed Ednrb was found in both groups (Figure 2.6B). There was no
significant difference (p>0.05) between the amount of Ednrb +/GFP+ melanoma
cells in wild-type and experimental tumors (Figure 2.6C). Immunostaining showed
that a large number of GFP- cells were positive for Ednrb (Figure 2.6A).
Additionally, flow cytometry plots revealed a large and well-defined population of
GFP-/Ednrb+ cells (Figure 2.6B). These observations suggest that Ednrb is
expressed in stromal cells.
Ednrb expression in the melanoma microenvironment
To further characterize the populations of non-tumorigenic cells present in the
TME, tumors were stained with different markers of stromal cells and analyzed
using flow cytometry. Fibroblasts were detected using CD140a (PDGF-R) marker
(Betsholtz, Karlsson and Lindahl, 2001), endothelial cells were labeled with CD146
antibody (Bardin et al., 2001) and leukocytes were identified using the panleukocyte marker CD45 (Trowbridge and Thomas, 1994). The presence of immune
cells from the myeloid lineage (Misharin et al., 2013) were assessed using the
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following markers: F4.80 for macrophages (Austyn and Gordon, 1981), Ly6G for
neutrophils (Daley et al., 2007) and CD11c for DCs (Osugi, Vuckovic and Hart,
2002). Lastly, cells from the lymphoid lineage, namely natural killer (NK) cells,
CTLs, and Tregs were detected using NK1.1 (Stenström et al., 2005), CD8a
(Bierer et al., 1989) and CD25 (IL-2Rα) (Lee, 2017) markers, respectively.
All markers used stained positively demonstrating that the YUMM1.7-GFP
melanoma microenvironment is very complex and comprised of a mixture of
stromal cells (Figure 2.7). Overall, the number of non-malignant cells in tumors
resulting from subcutaneous injections in wild-type and K5-Edn3 tumors was not
significantly different (p>0.05). The same pattern was observed in intradermal
tumors (p>0.05) (Figure 2.7). One crucial exception was observed for Tregs. In
both subcutaneous and intradermal injection-generated melanomas there were
approximately two times more Tregs in K5-Edn3 tumors when compared to wildtype tumors (p<0.01) (Figure 2.7C). This finding indicates that when Edn3 is
present in the melanoma microenvironment there is an enrichment of intratumoral
Tregs.
Immunofluorescence staining for Ednrb and the pan-leukocytes marker CD45
revealed that in both wild-type and experimental tumors there were several
immune cells that expressed Ednrb (Figure 2.8). To further characterize the
immune cell populations that expressed Ednrb, tumors were again dissociated and
stained for flow cytometry analysis using different markers for stromal cells and costained with Ednrb antibody. All assessed stromal cells expressed Ednrb (Figure
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2.9) but the exact populations of cells varied depending on the tumor location.
Subcutaneous tumors in K5-Edn3 mice exhibited more Ednrb+ endothelial cells
(Figure 2.9A) and CTLs (Figure 2.9C) than wild-type tumors (p<0.05), a pattern
not replicated in intradermal tumors (p>0.05). On the other hand, intradermal
tumors in K5-End3 mice showed more DCs (Figure 2.9B) that expressed Ednrb
(p<0.05), a trend not observed in subcutaneous tumors (p>0.05). Treg was the
only population that consistently expressed high levels of Ednrb in both
subcutaneous and intradermal tumors in K5-End3 mice (p<0.05) (Figure 2.9C).
This result corroborates the previous finding that the endothelin axis affects
intratumoral Tregs.
Ednrb expression in human melanoma
Lastly, I investigated whether the findings from YUMM1.7-GFP melanoma
mouse model are relevant for melanoma patients. Publicly available RNA-seq data
of melanoma samples from 19 patients (Tirosh et al., 2016) showed that EDNRB
is expressed by melanoma cells and several populations of stromal cells in the
TME (Figure 2.10A). In contrast to YUMM1.7-GFP tumors, malignant cells in the
human melanoma TME highly expressed EDNRB. As noticed in the YUMM1.7GFP tumors, fibroblasts, endothelial cells, macrophages, T, and NK cells
expressed different levels of EDNRB. T cells exhibited the highest level of EDNRB
expression in melanoma microenvironment. Next, the expression of EDNRB in
intratumoral Tregs was assessed. Tregs were defined as the subpopulation of T
cells expressing CD25 or FOXP3. There were few intratumoral Tregs that
expressed EDNRB in melanoma tumors (Figure 2.10B). These data are in
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accordance with the findings in the YUMM1.7-GFP tumors and suggest that
endothelin

signaling

is

important

for

stromal

cells

in

the

melanoma

microenvironment, particularly Tregs.
2.3.

Discussion

Notwithstanding initial controversy (Kikuchi et al., 1996), Ednrb has long been
demonstrated to be overexpressed in aggressive melanomas. Indeed, Edn3/Ednrb
signaling is currently considered a marker for melanoma progression (Demunter
et al., 2001). The present study strengthens these earlier findings showing that
overexpression of Edn3 in the melanoma microenvironment increases tumor
aggressiveness. Larger and metastatic melanoma were developed when primary
tumors were exposed to a microenvironment rich in Edn3. Similar results were
observed using YUMM1.7 cell line, which harbor BrafV600E (Meeth et al., 2016), and
B16F10, a melanoma cell line considered Braf wild-type (Melnikova et al., 2004;
Hooijkaas et al., 2012). Oncogenic BRAFV600E is found in about 50% of human
melanomas (TCGA, 2015). Findings from the present study suggest that
endothelin signaling is relevant to a broad range of melanomas, including
BRAFV600E and BRAF wild-type. It should be noted that endothelin might be crucial
for BRAFV600E mutated melanomas. Recent reports have shown that melanoma
treated with BRAFi tend to have increased expression of both Ednrb and Edn1
(Asundi et al., 2014; Smith et al., 2017). Thus, combinatory treatments targeting
endothelin signaling and oncogenic BRAF might be an effective therapeutic
approach for a particular subset of melanoma patients.
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Despite the canonical role of Edn3/Ednrb axis during melanoma progression,
to this date it is not clear the cellular distribution of endothelin signaling
components in the melanoma microenvironment. In vitro and in vivo expression of
EDN1 (Chiriboga et al., 2016) as well as EDN3 (Tang et al., 2008) have been
described in human melanoma cells. Recently, an in vitro study showed that EDN1
mediates the communication between endothelial and melanoma cells and
enhances their vasculogenic ability (Spinella et al., 2014). Expression of EDN1
was also detected in intratumoral macrophages from melanoma biopsies
(Chiriboga et al., 2016). EDNRB expression in melanoma has been mostly
described in melanoma cell lines (Yohn et al., 1994; Lahav, Heffner and Patterson,
1999; Bagnato et al., 2004; Asundi et al., 2011). Although EDNRB expression is
reported in patients with melanoma (Bittner et al., 2000; Demunter et al., 2001),
the precise cellular type expressing the receptor in the TME had not been
addressed. In this respect, Ednrb expression was detected in GFP + melanomas
cells from YUMM1.7-GFP tumors. However, no difference in the amount of
GFP+/Ednrb+ was found when K5-Edn3 and wild-type tumors were compared. Yet,
in both control and experimental YUMM1.7-GFP tumors the expression of Ednrb
was detected in a small percentage of melanoma cells. Many non-malignant cells
expressed Ednrb in YUMM1.7-GFP tumors, suggesting a possible environmental
role of endothelin signaling in the melanoma microenvironment. Thus, stromal
activation of endothelin signaling might be central to the aggressive phenotype of
K5-Edn3 tumors. In breast cancer, the role of stromal Ednrb has been explored in
detail. Injection of breast cancer cells overexpressing Ednra generated tumors with
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diminished growth and metastatic potential in Ednrb deficient rat. Lack of stromal
Ednrb did not affect angiogenesis but considerably impaired the infiltration of
immune cells and cytokine production resulting in reduced tumor aggressiveness.
The absence of Ednrb in the TME decreased the recruitment of TAMs and the
amount of pro-inflammatory cytokine TNF-α. In contrast, the amounts of T
lymphocytes and NK cells, as well as IL-10 cytokine were not affected by the
deficiency of Ednrb in the TME (Binder et al., 2009).
Melanoma microenvironment is comprised of several cell types. Tirosh and
colleagues elegantly described different populations of stromal cells existing in
human metastatic melanoma microenvironment. CAFs and endothelial cells
together with NK and macrophages represent a small percentage of melanoma
stroma. The majority of melanoma stroma consists of B lymphocytes and T cell
subtypes including CD8, CD4, and Treg (Tirosh et al., 2016). Basic
characterization of YUMM1.7 tumors revealed that these melanomas have
considerable immune infiltrate. As opposed to human melanomas the majority of
immune infiltrate was comprised of macrophages. Lymphocytes represented less
than 1% of immune cells in the microenvironment (Meeth et al., 2016). A more
sophisticated portrayal of the melanoma immune infiltrated from a different
BrafV600E mutated mouse melanoma cell line (BPD6) showed the presence CTLs,
DCs, TAMs and myeloid-derived suppressor cells (MDSCs) in the TME (Liu et al.,
2018).
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The above-mentioned findings were confirmed in this study by demonstrating
that YUMM1.7-GFP melanoma microenvironment is comprised of CAFs,
endothelial cells and a variety of leukocytes including macrophages, neutrophils,
DCs, NK, CTLs and Tregs. The higher amount of T cells in YUMM1.7-GFP tumors
compared to the original YUMM1.7 cells might be explained by differences in the
genetic background of mice used in the present study. In order to make the
YUMM1.7 cells syngeneic (that is, genetically identical) to C57BL/6 mice, the
YUMM1.7 cells were generated in transgenic mice after a series of backcrosses
with C57BL/6 mice (Meeth et al., 2016). In contrast, the K5-Edn3 transgenic mice
and their wild-type counterparts were generated using mice from C57BL/6 and
FVB/N genetic backgrounds (Garcia et al., 2008). Therefore, the YUMM1.7-GFP
cells might not be syngeneic to the K5-Edn3 mice. Upon injection in
immunocompetent K5-Edn3 mice, YUMM1.7-GFP cells might have induced a
strong immune response, which may explain the discrepancy in the T cell infiltrates
of YUMM1.7 and YUMM1.7-GFP tumors. Another reason could be the fact that
YUMM1.7-GFP cells were GFP labeled using lentivirus. GFP is a protein originated
from jellyfish that can induce immune responses in immunocompetent mice (Day
et al., 2014), a reaction also triggered by viral particles of lentivirus vector (Nayak
and Herzog, 2010).
The present study showed for the first time that Ednrb is expressed in several
cell populations within melanoma microenvironment. The microenvironmental role
of endothelin signaling has been explored in many tumor types other than
melanoma. Endothelin derived from colorectal cancer cells acts in a paracrine
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fashion on endothelin receptors exhibited by fibroblast and stimulates its growth,
migration, and contraction. Blockage of both EDNRA and EDNRB efficiently
inhibited the EDN1 induced effects in colonic fibroblasts (Haque et al., 2013). In
response to EDN1, CAFs reduce the expression of genes associated with
inflammation, namely IL-8 and SMAD5 (Knowles et al., 2012). This suggests that,
although considered a pro-inflammatory cytokine (Nett et al., 2006), in some
contexts endothelin might negatively regulate the inflammatory milieu in the TME.
Stromal endothelin is classically associated with angiogenesis. Indeed, high
expression of EDN1 is correlated with neovascularization in ovarian cancer
(Salani, Castro, et al., 2000). A mechanism employed by mesenchymal stem cells
(MSC) that contributes to endothelin-induced angiogenesis in the TME has
recently been described. MSCs produce IL-6, which controls the secretion of EDN1
by colorectal cancer cells. Endothelin promotes ERK and Akt phosphorylation in
endothelial cells, thus increasing endothelial cells recruitment and formation of new
blood vessels (Huang et al., 2013). Transcriptional profile of endothelial cells from
ovarian cancer revealed that more aggressive tumors have less tumor infiltrates
lymphocytes (TIL) because of EDNRB overexpression. EDNRB decreases the
expression of adhesion molecule ICAM-1 and consequently prevents recruitment
of CTLs to the TME. Endothelin attenuates lymphocyte clustering to endothelial
cells even in the presence of pro-inflammatory cytokine TNF-α. Therefore, EDNRB
activation in endothelial cells present in the TME creates an endothelial barrier
sustaining the immune-privileged microenvironment. Preclinical studies showed
that EDNRB blockage enhances otherwise ineffective immunotherapy strategies
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increasing CD8+ homing to the TME. Targeting EDNRB also promotes activation
of anti-tumor lymphocytes as shown by the upregulation of IFN-γ and IL-2
cytokines (Buckanovich et al., 2008). Thus, EDNRB activation in the TME
suppresses T cell recruitment facilitating immune escape and EDNRB antagonists
can be used in combination with immunotherapy to improve anti-tumor immune
response (Kandalaft et al., 2009, 2011). EDNRA seems to increase ICAM-1
expression on endothelial cells enhancing the recruitment of tumor inhibitory
immune cells (Coffman et al., 2013). Hence, EDNRA activation in the TME is
important for anti-tumor response while EDNRB stimulation prevents immune
response against tumor cells (Aubert and Juillerat-Jeanneret, 2016). This data is
to a certain extent conflicting with the observation that subcutaneous tumors in K5Edn3 mice had great quantities of endothelial cells that express Ednrb while
exhibiting more Ednrb+ CTL. The fact that K5-Edn3 tumors were larger and
metastatic suggests that the effect of Ednrb in subcutaneous YUMM1.7-GFP
tumors is not restricted to the recruitment of CTLs. This effect might be related to
other stromal population such as Tregs, which can further inhibit tumor-specific
CTLs.
Endothelin signaling is an important regulator of DCs function and survival.
Activation of immature DCs with TNF-α induce human DCs to secrete endothelin
and to express endothelin receptors. EDNRA stimulation enhances antigen
presentation by DCs as well as production of IL-12, a major regulator of T H1
polarization. On the other hand, activation of EDNRB prevents DCs activation.
These data suggest that endothelin might have an autocrine effect on DCs and the
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balance of endothelin receptors is involved in the generation of T H1 response
(Guruli et al., 2004). The negative regulatory effect of Ednrb in anti-tumorigenic
cells such as DCs might explain the fact that K5-Edn3 tumors are more aggressive
even though they had a higher number of Ednrb+ DCs.
The present study supports the hypothesis that endothelin signaling may have
multiple effects in melanoma microenvironment given that different populations of
stromal cells expressed Ednrb in the YUMM1.7-GFP tumors. Importantly, this is
the first report of Ednrb expression in NK cells and Tregs in TME. In both control
and experimental YUMM1.7-GFP melanomas, Ednrb expression was detected in
anti-tumor cells including CTLs, NK and DCs as well as pro-tumorigenic cells,
namely CAFs, TAMs, and Tregs. The fact that Ednrb expression is detected in
both anti- and pro-tumorigenic cells suggests potential opposite functions of
endothelin signaling in the melanoma microenvironment. Thus, the balance of
endothelin signaling activation among stromal cells that antagonize or promote
tumor development determines the fate of melanoma progression. Given that K5Edn3 tumors have a more aggressive phenotype, it is reasonable to assert that in
Edn3-rich microenvironment the net result favors the effect of endothelin in protumorigenic cells.
Treg is the only population that is numerically different when K5-Edn3 tumors
are compared to wild-type tumors. Therefore, it is tempting to claim that Tregs are
responsible for creating an immunosuppressive environment inside melanoma
tumors,

allowing

for

the

escape

from
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immunosurveillance.

Aggressive

glioblastomas express high levels of EDNRB and show reduced infiltration of CTL
along with increased number of Tregs. This data supports the notion that activation
of stromal EDNRB suppresses host anti-tumor immunity (Nakashima et al., 2016).
It is not clear whether the augmented amount of intratumoral Ednrb + Tregs in the
K5-Edn3 tumors is a consequence of increased Treg recruitment, proliferation or
differentiation from conventional T cells. Finally, EDNRB + Tregs were detected in
the human metastatic melanoma microenvironment suggesting that Tregs might
respond to EDN1 and EDN3 present in human melanomas and orchestrate
immunosuppression accountable for melanoma aggressiveness. Together, the
results presented here support the use of EDNRB blockage in combination with
immunotherapy

(Buckanovich et al., 2008) as a therapeutic approach to be

considered for patients with aggressive melanomas.
2.4.

Methods
Mice and genotyping

The K5-tTA; TRE-Edn3-lacZ (K5-Edn3, for simplicity) transgenic mice were
generated in our laboratory (Garcia et al., 2008). K5-Edn3 mice constitutively
overexpress Edn3 in the skin using a tetracycline-inducible system. Transgenic
expression of Edn3 is driven by the tTA activator in the regulatory region of the
Bos taurus gene for Keratin 5. Mice from K5-tTA; TRE-Edn3-lacZ intercrosses that
harbored either K5-tTA or TRE-Edn3-lacZ transgene were denominated wild-type
due the lack of transgenic overexpression of Edn3. A small piece of mouse tail was
used as a DNA source for genotyping. After DNA extraction PCR was carried out
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using the following primers: 5’-CCAGGTGGAGTCACAGGATT-3’ and 5’ACAGAGACTGTGGACCACCC-3’

for

K5-tTA

transgene

and

5’-

AGGCCTGTGCACACTTCTGT-3’ and 5’-TCCTTGTGAAACTGGAGCCT-3’ for
the TRE-Edn3-lacZ transgene. All animals were housed in the University Animal
Care Facility at Florida International University. The study was approved by the
Institutional Animal Care and Use Committee (IACUC) at Florida International
University protocol number 16-018.
Cell lines
YUMM1.7, a gift from Dr. Marcus Bosenberg (Yale University), and B16F10
murine melanoma cell (ATCC) lines were labeled with GFP using recombinant
lentivirus pHIV-Ednrb-EGFP. The lentivirus transduction procedure was carried
out at Florida International University Tissue Cell Culture Facility. The generation
of GFP labeled cells was approved by Institutional Biosafety Committee (IBC)
protocol number 16-027. YUMM1.7-GFP cells were cultured with DMEM/F-12
supplemented with 10% fetal bovine serum and penicillin/streptomycin. B16F10GFP cells were cultured in supplemented DMEM medium.
Tumor cell injection
A total of 100,000 melanoma cells were injected in the shaved flank of K5-Edn3
or wild-type mice. For subcutaneous injection cells were resuspended into 100µl
of PBS and injected under the skin using 25G needle. For intradermal injection
cells were resuspended into 50µl of PBS and injected under the superficial layer
of epidermis using 30G needle (Shimizu, 2004). Tumor length and width were
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measured twice a week using a digital caliper. Tumor volume was calculated using
the following formula: volume = (length x width x width)/2 (Cintolo et al., 2016).
Mice were euthanized when tumors reached 2 cm 3 of volume. Statistical analysis
was carried out with Student T-Test and considered to be significantly different at
p<0.05.
Flow Cytometry
Harvested tumors were minced finely with a scalpel blade and dissociated
using collagenase/dispase (Roche 10 269 638) for 45min followed by digestion
with trypsin 0.25% at 37°C for 5min. Cell suspension was filtered using 40µM cell
strainer and red blood cells were lysed with ACK lysis buffer. Single-cell
suspension was stained at 4°C for 30min using the following phycoerythrinconjugated antibodies: CD140 (0.25µg, Biolegend, 135905), CD146 (0.06µg,
Biolegend,

134703),

CD45

(0.25µg,

Biolegend,

103105),

F4/80

(1µg,

eBiosciences, 12-4801-82), Ly6G (0.25µg, Biolegend, 127607), CD11c (0.25µg,
Biolegend, 117307), NK1.1 (0.25µg, Biolegend, 108707), CD8a (0.25µg,
Biolegend, 100707) and CD25 (1µg, Biolegend, 102007). Single-cell suspension
was also stained with unconjugated rabbit Ednrb antibody (1:200, Proteintech,
20964-1-AP) followed by secondary staining using anti-rabbit PerCP/Cy5.5
antibody (1µg, Santa Cruz, sc-45109) or anti-rabbit Alexa 647 antibody (1:2000,
Abcam, ab150075). Fifty thousand events were acquired using Accuri C6 (BD
Biosciences) flow cytometer. The flow cytometric profile of each sample was
analyzed using FlowJo (TreeStar) software. Statistical analysis was carried out
with Student T-Test and considered to be significantly different at p< 0.05.
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Histological and Immunofluorescence Analysis
Tissues were fixed overnight with 4% paraformaldehyde (PFA), sequentially
incubated for 12h with 10% and 20% sucrose and cryo-embedded in OCT (Fisher
23-730-571). Cryosections (10µM) were incubated with blocking buffer (10%
normal serum, 0.3% Triton X-100, 1% BSA in 1x PBS) at room temperature for 1h.
Next, primary antibodies were diluted in dilution buffer (1% normal serum, 0.3%
Triton X-100, 1% BSA in 1x PBS) and added to cryosections for incubation at room
temperature for 1 hour or at 4°C overnight. Primary antibodies used: Edn3 (1:200,
Proteintech, 10674-1-AP), CD45 (1:200, Biolegend, 103101), Ednrb (1:400,
Proteintech, 20964-1-AP) and GFP (1:500, Aves Labs, GFP-1020). Antibody
against GFP was used in order to amplify the signal for immunostaining. Where
necessary, GFP fluorescence from lentivirus expression was photobleached by
treatment with 3% H2O2 in methanol and illumination on a fluorescent light box for
4 hours. After 3 sequential washes with 1xPBS, cryosections were incubated with
secondary antibody for 1 hour at room temperature. Secondary antibodies used:
anti-rabbit Alexa 488 (1:200, Invitrogen, A11008), anti-chicken Alexa 488 (1:500,
Abcam, ab150169), anti-rat Alexa 488 (1:200, Abcam, ab150159), anti-rabbit
Alexa 594 (1:200, Invitrogen, A11012). Then, slides were mounted with mounting
medium containing DAPI (Abcam, ab104139). Slides were visualized using Leica
DMRB fluorescent microscope and digital pictures were captured with a Leica
DFC450C camera.
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Publicly available RNA-seq data of melanoma samples
Single-cell gene expression data of melanoma samples was obtained from
GEO repository, access number GSE72056. Cell types were defined according to
the classification from Tirosh, et al. (2016). Treg cells were defined as the
subpopulation of T cells that have the expression level of CD25 or FOXP3> = 0.5
FPKM.
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2.5.

Figures

Figure 2.1 Mechanisms of action of endothelin in the TME
Endothelin signaling is activated in diverse populations of stromal cells in the TME.
Activation of endothelin receptors promotes growth and migration of fibroblasts as well
as production of ECM components and proteases. Ednrb activation on endothelial cells
stimulates angiogenic events such as proliferation and migration of endothelial cells.
Endothelin also controls the production of angiogenic factor VEGF. The differential
expression of endothelin receptors in endothelial cells regulates the expression of
adhesion molecules that eventually control the recruitment of lymphocytes to the TME.
The functions of APCs, namely DCs and macrophages, are also under the control of
endothelin signaling.
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Figure 2.2 Melanoma cell line and mouse model
A. Wild-Type mouse and transgenic mouse model K5-Edn3 used for subcutaneous and
intradermal injection of established YUMM1.7-GFP melanoma cells. B. Schematic
protocol used to generate YUMM1.7-GFP melanoma cell line as described in (Meeth et
al., 2016).
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Figure 2.3 Endothelin overexpression increases
subcutaneous YUMM1.7-GFP melanoma tumors

aggressiveness

of

A. Tumor volume of mice that received subcutaneous (n=8) injections of YUMM1.7GFP melanoma cells. B. GFP+ cells (green) in lungs of wild-type and K5-Edn3 mice
subcutaneously injected with YUMM1.7-GFP cells. *p<0.05
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Figure 2.4 Endothelin overexpression increases aggressiveness of intradermal
YUMM1.7-GFP melanoma tumors
A. Tumor volume of mice that received intradermal (n=13) injections of YUMM1.7-GFP
melanoma cells. B. GFP+ cells (green) in lungs of wild-type and K5-Edn3 mice
intradermally injected with YUMM1.7-GFP cells. *p<0.05
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Figure 2.5 Endothelin overexpression increases aggressiveness of intradermal
B16F10-GFP melanoma tumors
A. Tumor volume of mice that received intradermal (n=11) injections of B16F10-GFP
melanoma cells. B. GFP+ cells (green) in lungs of wild-type and K5-Edn3 mice
intradermally injected with B16F10-GFP cells. *p<0.05
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Figure 2.6 Ednrb is expressed in melanoma cells
A. Representative photomicrographs of immunofluorescence staining of cryosections of
intradermally injected YUMM1.7-GFP tumors in wild-type and K5-Edn3 mice for GFP and
Ednrb. White arrow showing double positive cells. B. Flow Cytometry plots of GFP+/Ednrb+
melanoma cells of subcutaneous and intradermal YUMM1.7-GFP tumors of wild-type and
K5-Edn3 mice. C. Percent quantification of flow cytometry data (n=3/group). *p<0.05.
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Figure 2.7 Populations of stromal cells present in the melanoma TME
Percent quantification of mesenchymal cells (A), myeloid (B) and lymphoid (C) cells in
subcutaneous and intradermal YUMM1.7-GFP tumors of wild-type and K5-Edn3 mice
(n=3/group). **p<0.01.
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Figure 2.8 Ednrb is expressed by stromal cells in the melanoma TME
Representative photomicrographs of immunofluorescence staining of cryosections of
intradermally injected YUMM1.7-GFP tumors in wild-type (A) and K5-Edn3 mice (B) for
CD45 (green) and Ednrb (red). White arrows showing double positive cells.
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Figure 2.9 Ednrb is expressed by a variety of cell types in the melanoma TME
Percent quantification of Ednrb+ mesenchymal cells (A), myeloid (B) and lymphoid (C)
in subcutaneous and intradermal YUMM1.7-GFP tumors of wild-type and K5-Edn3 mice
(n=3/group) *p<0.05, **p<0.01.
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Figure 2.10 EDNRB is expressed by a variety of cell types within the human
melanoma TME
A. Violin plots showing frequency of malignant and stromal cells expressing different
EDNRB levels from the single-cell RNA sequencing data of melanoma samples from 19
patients (Tirosh et al., 2016). B. Violin plot of EDNRB expression in Tregs cells. Treg
cells were defined as the subpopulation of T cells that have the expression level of CD25
or FOXP3> = 0.5 FPKM. Pre-processed RNA sequencing data were downloaded from
supplementary material.
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CHAPTER
3. Immunosuppressive role of Edn3 in the Melanoma Microenvironment
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3.1.

Introduction

The immunoediting concept suggests that the host immune system hampers
tumor formation while shaping tumor immunogenicity. Immunoediting occurs in a
stepwise process. During the elimination phase components of tumor
immunosurveillance system encounter and demolish emerging tumors. Cancer
cells that resist the forces of immunosurveillance are kept dormant during the
equilibrium phase. Lastly, in the escape phase tumor cells that became less
immunogenic form visible tumors. This last stage is empowered by the
immunosuppressive setting established in the TME (Schreiber, Old and Smyth,
2011).
As demonstrated in Chapter 2, the melanoma microenvironment is
characterized by infiltration of several immune cell populations. The intense
recruitment of immune cells to melanoma tumors is a consequence of melanoma
immunogenicity (Passarelli et al., 2017). Even though notably immunogenic,
melanoma develops diverse mechanisms to evade immune detection. Indeed,
melanoma is considered a highly immunosuppressive type of tumor (Umansky and
Sevko, 2012). Inside the TME, suppressive mediators including cytokines and cells
create an immunosuppressive network enabling tumors to escape from immune
detection and destruction by engaging components of the immunosurveillance
system (Liu, Workman and Vignali, 2016). Intratumoral regulatory T cells (Tregs)
play a central role in contributing to the formation of the immunosuppressive milieu.
Therefore, they support tumor development suppressing tumor-specific immune
responses in the TME (Chaudhary and Elkord, 2016).
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Tregs have strong immunosuppressive abilities that mediate self-tolerance,
prevent autoimmune diseases and limit excessive immune responses. Tregs are
a small population of CD4+ Helper T cells classically distinguished by the
constitutive expression of CD25 and FOXP3 markers (Lee, 2017). CD25, the αchain of IL-2 receptor, was used in the mid 90’s to identify a small subset of mouse
CD4+ Helper T cells responsible for maintaining self-tolerance (Sakaguchi et al.,
1995). Later it became clear that this population characterized as Tregs
overexpresses CD25 and is able to suppress self-reactive T cells in mice (SuriPayer et al., 1998) as well as in humans (Baecher-Allan et al., 2001; Ng et al.,
2001). Although CD25 is constitutively expressed by Tregs, non-suppressive cells
such as CD8+ and CD4+ T cells transiently upregulate CD25 during T cell activation
and inflammation (Chaudhary and Elkord, 2016; Liu, Workman and Vignali, 2016).
Thus, identification of Tregs exclusively by CD25 is inaccurate and inclusion of
other markers might be valuable (Fontenot et al., 2005).
In the early 2000’s the forkhead box P3 (Foxp3) gene was associated with the
phenotype of scurfy mice. These mice develop fatal autoimmune disease due to
spontaneous loss-of-function mutations in the Foxp3 gene (Brunkow et al., 2001).
Similarly,

humans

with

IPEX

syndrome

(Immune

dysregulation,

polyendocrinopathy, enteropathy, X-linked) harbor deleterious mutations in the
FOXP3 gene and develop strong autoimmune diseases (Bennett et al., 2001).
Shortly after the description of FOXP3 gene, studies from Sakaguchi and
Rudensky groups revealed that FOXP3 protein (also known as scurfin) is highly
expressed by Tregs and helped to coin FOXP3 as a master regulator of Treg
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function (Fontenot, Gavin and Rudensky, 2003; Hori, Nomura and Sakaguchi,
2003). FOXP3 regulates the expression of genes responsible for mediating Treg
suppressive features (Zheng et al., 2007; Frydrychowicz et al., 2017).
Notwithstanding a variety of functions that sustain immune homeostasis, Tregs
might also populate tumors promoting tolerance to tumor-associated antigens
(TAAs) and suppressing anti-tumor immunity (Nishikawa and Sakaguchi, 2010).
Tregs are routinely found in inflamed tumors that exhibit great amounts of CTLs
and TH1 cells (Togashi, Shitara and Nishikawa, 2019). Due to their highly
immunosuppressive features and infiltration in the TME, Tregs are considered a
critical hurdle to favorable outcome of immunotherapies (Chao and Savage, 2018).
Intratumoral Tregs may disrupt the mechanisms of immunosurveillance and
support tumor development (Yamaguchi and Sakaguchi, 2006; Takeuchi and
Nishikawa, 2016; Togashi, Shitara and Nishikawa, 2019). Depletion of tumor
resident Tregs results in increased infiltration of tumor inhibitory cells (Li et al.,
2010) accompanied by effective anti-tumor immune response (Shimizu et al.,
1999).
Tregs impair the immune response against tumors mediated by T H1 CD4+ T
Helper cells (Casares et al., 2003), DCs (Chen et al., 2017), CTLs (Chen et al.,
2005) and NK cells (Pedroza-Pacheco, Madrigal and Saudemont, 2013). Tregs
have four basic mechanisms of immunosuppression including inhibitory cytokines,
IL-2 consumption, cytolysis and modulation of DCs functions (Vignali, Collison and
Workman, 2008). A diagrammatic representation of the immunosuppressive
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mechanisms of Tregs that limit the anti-tumor immunity in the TME is shown in
Figure 3.1.
Tregs disrupt immune response against tumor through secretion of
immunosuppressive cytokines TGF-β and IL-10 (Yi et al., 2013). TGF-β impairs
the development, proliferation, and function of anti-tumorigenic cells in the TME
(Pickup, Novitskiy and Moses, 2013). Accordingly, TGF-β derived from Tregs
mitigates anti-tumor immunity (Hilchey et al., 2007). There is a positive correlation
between high levels of TGF-β and reduced survival in patients with melanoma
(Tang et al., 2015). Similarly, IL-10 allows evasion of tumor cells from immune
destruction in TME (Mannino et al., 2015) and high expression of IL-10 is
associated with poor prognosis for melanoma patients (Dummer et al., 1995;
Nemunaitis et al., 2001). A key mechanism of IL-10 immunosuppression is the
impairment of antigen presentation (Sato et al., 2011). IL-10 secreted by Tregs
hampers immune response against tumors in a contact-independent mechanism
(Bergmann et al., 2007). IL-35 is another cytokine required for maximal Treg
suppression action (Vignali, Collison and Workman, 2008). Tregs are the main
source of IL-35 in the TME and this cytokine limits the generation of tumor-specific
CTLs as well as promotes intratumoral T cell exhaustion. Furthermore, Tregspecific depletion of IL-35 hampers tumor growth (Turnis et al., 2016).
Although Tregs do not produce IL-2 (Papiernik et al., 1998), due to IL-2Rα
(CD25) overexpression they constitutively uptake the IL-2 available in the
microenvironment (Thornton and Shevach, 1998). Competition for IL-2
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concurrently results in Tregs proliferation and inhibition of effector T cell growth
since it depletes the IL-2 required for effector T cell propagation (de la Rosa et al.,
2004). Early in tumor development, when effector T cells are still producing IL-2,
the upregulation of IL-2Rα in Tregs reduces the availability of this cytokine limiting
T cell proliferation (Liu, Workman and Vignali, 2016).
Secretion of granzyme and perforin leading to cytolysis of target cells is
classically associated with activity of cytotoxic cells (i.e. CTLs and NK). After
encountering its target, a cytotoxic cell releases granule containing perforin and
granzymes. Perforin creates pores in the target cell allowing granzyme to access
the cytosol and activate caspases (Lieberman, 2003). Unexpectedly, upon
activation, Tregs were shown to express high levels of granzyme B (GZB) and
exhibited cytotoxicity against different human cell lines (Grossman et al., 2004).
GZB and perforin produced by intratumoral Tregs suppress the anti-tumor
response of NKs and CTLs. It is estimated that 5-30% of tumor resident Tregs
express GZB (Cao et al., 2007).
DCs functions are controlled by Tregs and this regulatory mechanism indirectly
affects the function of effector T cells given that functional DCs are required for
activation of T cells (Vignali, Collison and Workman, 2008). Tregs constitutively
express the inhibitory receptor CTLA-4 (Read, Malmström and Powrie, 2000).
CD28 exhibited on the surface of naïve T cells competes with CTLA-4 for B7
expressed by DCs. Notably, CTLA-4 has stronger affinity for B7. The interaction of
CTLA-4 with B7 co-stimulatory molecule inactivates DCs and consequently
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prevents the activation of effector T cells (Lee, 2017). Tregs employ CTLA-4 to
hamper tumor immunity as CTLA-4-deficient Tregs exhibit reduced suppression
which resulted in improved immune response against tumor (Wing et al., 2008).
Tregs represent only 2-10% of CD4+ T cells in the peripheral blood of healthy
patients. In contrast, it is estimated that Tregs account for 20-50% of CD4 + T cells
present in the TME (Takeuchi and Nishikawa, 2016; Togashi, Shitara and
Nishikawa, 2019). The prognostic value of Treg infiltrate for patients with cancer is
still contentious and depends on tumor site (DeLeeuw et al., 2012). In many types
of cancers heavy Treg infiltration is connected with reduced survival of patients
(Nishikawa and Sakaguchi, 2010; Chaudhary and Elkord, 2016). Still, the absolute
number of intratumoral Tregs is not always correlated with patients’ survival (Sato
et al., 2005). It has been suggested that increased ratio between Tregs and
effector lymphocytes is a more reliable prognostic indicator (Chaudhary and
Elkord, 2016) since it demonstrates that Tregs are efficiently suppressing antitumor immune responses (Takeuchi and Nishikawa, 2016). High incidence of
intratumoral Tregs is associated with poor prognosis in patients with melanoma
(Knol et al., 2011), glioblastoma (Sayour et al., 2015) and many carcinomas
including lung (Tao et al., 2012), pancreatic (Tang et al., 2014) and ovarian cancer
(Curiel et al., 2004). On the other hand, in patients with colon (Frey et al., 2010)
and gastric tumors (Haas et al., 2009), whose tumorigenesis are associated with
long term inflammation, the immunosuppression associated with Tregs provides a
shielding effect against tumor formation. Thus, a high number of intratumoral Tregs
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in these tumor types are linked to improved prognosis (Chaudhary and Elkord,
2016; Frydrychowicz et al., 2017).
Targeting of Tregs considerably improves tumor immunity and during the past
few years immunotherapy strategies aiming to mitigate Tregs suppressive
mechanisms have reached promising outcomes (Lee, 2017). Immunotherapy
using monoclonal antibodies against CTLA-4 (ipilimumab) promotes activation of
effector T cells (Maker, Attia and Rosenberg, 2005) resulting in improved outcome
for patients with metastatic melanoma (Schadendorf et al., 2015). The mechanism
of action of ipilimumab is still not completely understood. It is assumed that
ipilimumab prevents Tregs from obstructing effector T cells activation mediated by
DCs (Liu, Workman and Vignali, 2016; Lee, 2017). It has also been suggested that
ipilimumab selectively depletes Tregs through an antibody-dependent cellular
cytotoxic mechanism (Simpson et al., 2013).
Chronic inflammation and long-term immunosuppression are uncontrolled
immune events that impact tissue microenvironment and endorse tumor formation
and development (Quail and Joyce, 2013; Palucka and Coussens, 2016). Tregmediated immunosuppression in the melanoma microenvironment is a relevant
mechanism of escape from immune detection during the immunoediting process
(Jacobs et al., 2012). Endothelins are considered pro-inflammatory cytokines
given that they stimulate inflammatory response (Nett et al., 2006). Despite
extensive studies that explored the immunoregulatory features of endothelins,
how these cytokines negatively regulate immune response, particularly anti-tumor
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immunity, is still poorly understood. Furthermore, the effect of endothelin on
immunosuppressive cells such as Tregs has not been elucidated. The present
study addressed the inhibitory effect of endothelin signaling during the immune
response against melanoma.
3.2.

Results
Endothelin is required for immune escape of YUMMER1.7 cells

Highly immunogenic YUMMER1.7 cells were intradermally injected in wild-type
and K5-Edn3 mice to evaluate whether activation of endothelin signaling in the
melanoma microenvironment is required for immune escape. YUMMER1.7 cells
were originated from YUMM1.7 cells after rounds of UV radiation followed by clonal
selection. YUMMER1.7 cells have a higher mutation load compared to YUMM1.7
cells that elicited anti-tumor response. YUMMER1.7 cells exhibited tumor
regression after injection in immunocompetent mice. YUMMER1.7 cells generated
small tumors in wild-type mice 5 days after injections. These tumors began to
shrink 8 days after injection and completely regressed 19 days post-injection
(Figure 3.2). Initially, YUMMER1.7 tumors developed in K5-Edn3 mice had similar
growth rate to those in wild-type mice. However, after a short period of relapse,
tumors escaped regression and resumed growth at day 12. Tumor growth was
maintained even after the complete regression observed in wild-type tumors
(Figure 3.2). This finding suggests that the presence of endothelin in melanoma
microenvironment may promote evasion from immune destruction.
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Endothelin increases the expression of Tregs-associated markers
Real-time quantitative PCR was carried out to investigate whether
overexpression of Edn3 in the melanoma microenvironment affects the expression
of Treg-associated markers. qRT-PCR revealed that YUMM1.7-GFP melanoma
tumors from K5-Edn3 mice had increased expression of Foxp3, Tgf-β and Il-10
genes when compared to tumors from control mice (Figure 3.3).
Next, I sought to confirm if the augmented expression of these genes was
maintained at proteic level. The expression of FOXP3 protein in YUMM1.7-GFP
tumors was examined using Western Blotting. The result supported the qRT-PCR
data and showed that K5-Edn3 tumors exhibited remarkably higher expression of
FOXP3 when compared to wild-type tumors. FOXP3 expression in experimental
tumors was two times higher (p<0.05) than control tumors (Figure 3.4). TGF-β and
IL-10 are two inhibitory cytokines that mediates the suppressive functions of Tregs.
The expression of these immunosuppressive cytokines was evaluated using
different approaches. The visual inspection of four sections per tumor from
YUMM1.7-GFP tumors (n=4/group) did not detect TGF-β expression in wild-type
tumors while TGF-β expression was observed in the microenvironment of K5-Edn3
tumors (Figure 3.5). This result is in accordance with qRT-PCR data. Interestingly,
TGF-β expression was mostly detected in extracellular space suggesting
suppression by TGF-β occurs in a contact-independent manner. The production of
IL-10 cytokine in the YUMM1.7-GFP tumors was quantified using IL-10 ELISPOT.
In K5-Edn3 tumors there was a significantly increased number (p<0.01) of IL-10 +
spots when compared with wild-type tumors (Figure 3.6). K5-Edn3 tumors had on
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average 193 IL-10+ spots while wild-type tumors had an average number of 11 IL10+ spots. This result corroborated the observation that at the mRNA level IL-10
expression is higher in K5-Edn3 tumors.
Quantification of GZB expression was performed by immunofluorescence in
YUMM1.7-GFP tumors. Experimental tumors showed approximately four times
more GZB expression (p>0.01) when compared to control tumors (Figure 3.7). To
confirm that GZB expression is restricted to Tregs, FOXP3 should have been costained with GZB. Unfortunately, FOXP3 antibody did not work properly for
immunofluorescence staining. Therefore, due to technical limitations it was not
possible to rule out that other cell types in melanoma TME also express GZB.
Ednrb+ Tregs suppress cytotoxic cells
To address whether the anti-tumor response in melanoma is counterbalanced
by intratumoral Tregs expressing Ednrb, flow cytometric data was used to calculate
the relative number of Ednrb+ Tregs to CTLs. This approach can demonstrate if
Tregs are efficiently suppressing anti-tumor immune responses. K5-Edn3 tumors
exhibited an Ednrb+ Tregs/CTL ratio three times higher (p<0.05) compared to wildtype tumors (Figure 3.8). This finding indicates that activation of endothelin
signaling in Tregs prevents expansion of CTLs.
Immune checkpoint and Ednrb inhibitor decreased melanoma growth
To test whether the combination of immune checkpoint inhibitor with Ednrb
blockage is a viable strategy to prevent melanoma growth, K5-Edn3 mice bearing
YUMM1.7-GFP tumors were treated with CTLA-4 blocking antibody alone or in
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combination with Ednrb inhibitor (BQ-788) for three weeks. Mice in the control
group received treatment of DMSO along with isotype control and developed large
tumors by the end of the treatment (average volume of 1,829 mm 3) (Figure 3.9A).
Tumors treated with anti-CTLA-4 exhibited a growth rate similar to the control
group until day 13 of treatment. After that day, anti-CTLA-4 treatment significantly
prevented tumor growth (p<0.05) (Figure 3.9A). Tumors treated with anti-CTLA-4
had an average volume of 432.03 mm3 when treatment was concluded. Treatment
exclusively with BQ-788 and in combination with anti-CTLA-4 remarkably reduced
melanoma growth (p<0.0001) (Figure 3.9A). Indeed, some mice in these groups
showed complete tumor regression. Tumors responded to BQ-788 earlier than
anti-CTLA-4 although the volume of tumors from these groups were not statically
different (p>0.05) (Figure 3.9A). The response to BQ-788 was so accentuated that
no difference (p>0.05) was observed when tumors treated only with BQ-788 were
compared to tumors treated with combination of BQ-788 and anti-CTLA-4 (Figure
3.9B). The average tumor volume observed in BQ-788 group at the end of
treatment was 8.8 mm3 and the combination group had an average volume of
11.18 mm3. Altogether this data suggests that YUMM1.7-GFP tumors exposed to
high levels of Edn3 are sensitive to immune checkpoint inhibitor as well as to Ednrb
blockage, although the response to BQ-788 seems to be more noticeable.
Endothelin suppresses expression

of inflammatory proteins in

melanoma TME
In order to identify novel factors impacted by endothelin overexpression in the
melanoma microenvironment I performed an unbiased cytokine screen.
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YUMM1.7-GFP tumors from wild-type and K5-Edn3 mice were harvested and
changes in protein expression were analyzed by RayBiotech ® Quantibody Mouse
Cytokine Antibody Array. After normalization to internal controls, a group of 15
cytokines was identified as differentially expressed (p<0.05) when wild-type and
K5-Edn3 were compared (Figure 3.10A). K5-Edn3 tumors exhibited decreased
levels of IL-28 (p<0.05) as well as the classical pro-inflammatory cytokine IL-17E
(p<0.01) (Figure 3.10B). These results are in accordance with my previous findings
and confirmed that endothelin signaling promotes immunosuppression in the
melanoma microenvironment.
3.3.

Discussion

The present study suggests that endothelin is an important component of the
immunoediting process that takes places in melanoma development, particularly
during the escape phase. YUMMER1.7 melanoma cells, which harbor a high
mutational load, developed tumors in immunocompetent mice. These tumors were
possibly detected by the tumor immunosurveillance system eliciting anti-tumor
responses and tumor regression. A recent study demonstrated that YUMMER1.7
tumor regression in immunocompetent mice is a process that relies on cells from
the adaptive immune response (Wang et al., 2017). Tumors growing without
abundant endothelin in the microenvironment regressed completely around 20
days after injection. Conversely, when melanoma tumors grew in an End3-rich
microenvironment they overcame immune destruction and evolved to tumors that
did not regress. Therefore, the presence of endothelin in melanoma
microenvironment facilitates the evasion from anti-tumor immunity.
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Tregs suppress immune response against tumors and are considered central
mediators for the escape from immune destruction (Takeuchi and Nishikawa,
2016). Tregs infiltration is routinely found in patients with melanoma and these
cells are considered functionally immunosuppressive (Vence et al., 2007). This
study supports the notion that Tregs orchestrate immunosuppression in melanoma
microenvironment. Enrichment of Tregs in melanoma tumors is generally
associated with poor survival (Miracco et al., 2007; Mougiakakos et al., 2010;
Gerber et al., 2014), although some studies did not find a correlation between Treg
infiltration and melanoma outcome (Hillen et al., 2008; Ladányi et al., 2010). This
discrepancy is probably due to the use of absolute number of Tregs rather than
relative amount of Tregs to effector lymphocytes. Several preclinical studies have
shown that a better outcome is achieved when melanoma tumors exhibited a ratio
Treg/effector lymphocyte that favors effector cells (Nair et al., 2007; Cohen et al.,
2010; Shabaneh et al., 2018). Accordingly, less aggressive YUMM1.7-GFP tumors
had a smaller ratio of Ednrb+ Tregs/CTLs when compared to aggressive tumors.
This finding suggests that more CTLs are present in melanomas when there is no
activation of endothelin signaling in Tregs. Thus, tumor immunity in melanoma
microenvironment is hampered when Tregs are exposed to high levels of Edn3.
Tregs are defined by the constitutive expression of CD25 and FOXP3 markers
(Lee, 2017). Yet, CD25 is transiently expressed by CD8 + and CD4+ T cells (Liu,
Workman and Vignali, 2016). It is thus possible that cells other than Tregs might
have contributed to the increased numbers CD25+ cells observed in tumors
growing in K5-Edn3 mice. FOXP3 is regarded as a reliable marker for murine
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Tregs (Vignali, Collison and Workman, 2008). K5-Edn3 tumors showed
augmented FOXP3 expression at mRNA and proteic levels relative to wild-type
tumors confirming that there is an enrichment of Tregs when End3 is
overexpressed in melanoma microenvironment. The mechanism adopted by
endothelin to govern the accumulation of Tregs in K5-Edn3 tumors remains
unclear. It is possible that endothelin impacted Tregs recruitment, proliferation, or
conversion of conventional T cells into Tregs (Lee, 2017). The main mechanism
responsible for Treg accumulation in tumors relies on chemokines system (Wang,
Lee and Kim, 2012; Plitas et al., 2016). Given that the chemical structure of mature
endothelin is very similar to that of other chemokines (Grimshaw, Wilson and
Balkwill, 2002) it is tempting to claim that endothelin regulates the chemotactic
trafficking of Tregs to melanoma microenvironment.
Tumor intrinsic factors such as driver mutations might tolerate antitumor
immunity in addition to promoting tumor formation (Togashi, Shitara and
Nishikawa, 2019). A recent study demonstrated that early during tumorigenesis
BRAFV600E is responsible for recruitment of Tregs to melanoma microenvironment
and impaired tumor surveillance (Shabaneh et al., 2018). Importantly, Tregs are
required for immune escape of BRAFV600E mutated YUMMER1.7 melanoma cells
(Wang et al., 2017). The current study validates these previous findings.
YUMM1.7-GFP melanoma cells, which harbor BRAFV600E mutation, developed
tumors that express Treg marker FOXP3 in both wild-type and K5-Edn3 mice.
Nevertheless, in K5-End3 tumors FOXP3 expression was augmented. This
suggests that in an endothelin-rich microenvironment Tregs suppressive functions
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are amplified. FOXP3 is considered the master regulator of Treg function (Togashi,
Shitara and Nishikawa, 2019). Indeed, this transcription factor regulates the
expression of genes that mediate the immunosuppressive features of Tregs
including surface proteins CD25 and CTLA-4 and effector molecules IL-10 and
GZB (Zheng et al., 2007). Genome-wide methylation comparison between human
Treg and naïve T cell revealed 127 regions differentially methylated (RDM).
Interestingly, EDNRB gene is among these RDMs in Tregs. EDNRB gene is
hypomethylated and is considered a putative binding site of FOXP3. This finding
implicates that EDNRB expression in Tregs is under the control of transcription
factor FOXP3 (Zhang et al., 2013).
Levels of immunosuppressive cytokines TGF-β and IL-10 were elevated in K5Edn3 tumors at both mRNA and proteic level indicating that endothelin stimulates
the secretion of immunosuppressive cytokines in melanoma microenvironment.
Since K5-Edn3 tumors exhibited enrichment of Tregs it is possible that these
suppressive cells accounted for the augmented level of TGF-β and IL-10 in an
endothelin-rich microenvironment. There is limited information regarding the
association between endothelins and immunosuppressive cytokines IL-10 and
TGF-β. It has been demonstrated that in mouse aorta and mesenteric artery IL-10
antagonizes the vascular responses to Edn1 (Giachini et al., 2009). Consequently,
in the context of vascular stimulation endothelin and IL-10 have conflicting effects.
This is in contrast with the observed functions of endothelin and IL-10 in K5-Edn3
tumors. Consistent with the present study, macrophages treated with endothelin
exhibited increased expression of IL-10 and TGF-β (Soldano et al., 2016).
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Furthermore, TGF-β and Edn1 displayed synergistic effects during vascular
remodeling (Lambers et al., 2013).
Tregs also employ contact-dependent mechanism to suppress effector cells,
including production of GZB. It has already been demonstrated that production of
GZB by intratumoral Tregs suppresses the anti-tumor response of NKs and CTLs
(Cao et al., 2007). Single-cell RNA sequencing showed that Tregs isolated from
melanoma tumors express GZB (Tirosh et al., 2016). GZB expression was
accentuated in K5-Edn3 tumors. Given the increased ratio Ednrb+ Tregs/CTLs in
K5-Edn3 tumors it is possible that the activation of endothelin signaling in Tregs is
responsible for Treg-mediated cytolysis of CTLs. However, it is important to note
that other cell types such as CTLs and NKs also express GZB (Lieberman, 2003).
The data presented in this study is not sufficient to claim that in YUMM1.7-GFP
tumors GZB expression is restricted to Tregs. Given that K5-Edn3 tumors exhibited
a higher number of Tregs it is reasonable to propose that Tregs influenced the
augmented GZB expression in K5-Edn3 tumors.
Altogether these data suggest that when YUMM1.7-GFP tumors are exposed
to a microenvironment rich in Edn3, the expression of markers associated with
Treg function is augmented. Interestingly, markers of both contact-independent
and contact-dependent mechanisms of Treg suppression were enhanced in K5Edn3 tumors. These findings implicate that endothelin signaling is required for
immunosuppressive features of Tregs. Unexpectedly, endothelin which is

133

generally

considered

a

pro-inflammatory

cytokine

seems

to

play

an

immunosuppressive role in the microenvironment of YUMM1.7-GFP melanoma.
Therapeutic approaches aiming to block Treg functions have produced clinical
success in melanoma. Immunotherapy using monoclonal antibodies against
CTLA-4 (ipilimumab) results in improved outcome for patients with metastatic
melanoma (Schadendorf et al., 2015). Blockage of Ednrb efficiently reduced
melanoma growth in vitro and in vivo (Lahav, Heffner and Patterson, 1999). The
present study investigated for the first time if the combination of Ednrb inhibitor
(BQ-788) with immunotherapy using CTLA-4 blocking antibody is a therapeutic
strategy that abrogate melanoma growth more effectively. YUMM1.7-GFP tumors
exposed to a microenvironment rich in Edn3 responded to immune checkpoint
inhibitor. YUMM1.7-GFP tumors exhibited a delayed response to anti-CTLA-4,
which has been previously reported in patients with melanoma (Saenger and
Wolchok, 2008). The mechanisms of action of CTLA-4 blocking antibody was not
explored in detail in the K5-Edn3 mouse model. However, based on the elevated
number of Tregs when YUMM1.7-GFP tumors are exposed to high levels of Edn3
is possible to argue that anti-CTLA-4 prevented the T cell activation mediated by
Tregs or even promoted Treg depletion (Togashi, Shitara and Nishikawa, 2019).
Several in vitro and preclinical studies have demonstrated the anti-cancer effect
of Ednrb blockage in melanoma (Lahav, Heffner and Patterson, 1999; Rosanò et
al., 2004; Smith et al., 2017). The anti-tumor effect of Ednrb inhibition was more
pronounced than immune checkpoint inhibitor in YUMM1.7-GFP tumors. Along
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these lines, the potent effect of BQ-788 against melanoma has already been
shown to be stronger than other therapeutic approaches such BRAF inhibition
(Smith et al., 2017). Combination of anti-CTLA-4 with BQ-788 produced the same
anti-tumoral effect that BQ-788 alone suggesting that Ednrb blockage is sufficient
to prevent melanoma growth. The anti-tumor activity of anti-CTLA-4 was probably
restricted to Tregs. Conversely, the striking anti-melanoma effect of BQ-788 might
have been the consequence of Ednrb signaling blockage in Tregs as well as other
cells in the TME. A recent study demonstrated that intratumoral administration of
BQ-788 in melanoma patients reduced tumor growth and enhanced immune cell
infiltration (Wouters et al., 2015). These data along with the present study support
the idea that Ednrb blockage might effectively be employed as a therapeutic
strategy for melanoma patients that express high levels of components of
endothelin signaling.
The present study indicates that endothelin presence in melanoma
microenvironment enables the formation of an immunosuppressive milieu
facilitating escape from tumor immunity. Tumors growing in abundance of
endothelin exhibited remarkable reduction on the expression of chemokines and
pro-inflammatory cytokines. Surprisingly, in K5-Edn3 tumors there was a
significant reduction in the expression of chemokines CXCL11, CXCL2, CXCL12,
CCL12 and CCL9. Chemokines regulate the recruitment of different populations of
immune cells to TME (Nagarsheth, Wicha and Zou, 2017). Since immune cell
populations (other than Tregs) did not differ when wild-type and K5-Edn3 tumors
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were compared, it is possible that the presence of endothelin did not influence the
overall trafficking of immune cells to melanoma microenvironment.
IL-17 is a pro-inflammatory cytokine required for anti-tumor features of T H17
cells during tumor immunosurveillance (Grivennikov, Greten and Karin, 2010).
TH17 is an effector cell of tumor immunity and its presence in TME is associated
with diminished numbers of Treg and increased amounts of CTLs and NK cells
(Zou and Restifo, 2010). Reduction in the levels of IL-17F in K5-Edn3 tumors
indicated that endothelin impaired tumor immunity in the YUMM1.7-GFP
melanoma tumors. It has been shown that activation of EdnrA, but not Ednrb,
stimulates the production of IL-17 in TH17 cells (Tanaka et al., 2014). Based on the
observation that in presence of Edn3 there is downregulation of IL-17 it is plausible
to argue that endothelin receptors might play ambiguous roles in T H17 cells as they
do in DCs (Guruli et al., 2004). IL-28 is another cytokine that elicits anti-tumor
response (Numasaki et al., 2007). Downregulation of IL-28 cytokine in K5-Edn3
tumors was of particular interest given that the association between this cytokine
and endothelin has not been previously described. The reduced levels of IL-28 in
K5-Edn3 tumors corroborated the observation that endothelin weakened tumor
immunity.
During the last few years, a growing body of data have challenged the paradigm
that endothelin exclusively stimulates inflammatory response. Expression of Ednrb
on DCs decrease their maturation and survival suggesting that Ednrb negatively
regulates immune response (Guruli et al., 2004). Endothelin promotes
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macrophage polarization towards M2 phenotype, which are distinguished by their
anti-inflammatory features. Indeed, Edn1 treatment stimulates macrophages to
secrete immunosuppressive cytokines IL-10 and TGF-β (Soldano et al., 2016).
EDNRB expression on endothelial cells impairs the homing of anti-tumor immune
cells to TME (Aubert and Juillerat-Jeanneret, 2016). EDNRB decreases the
expression of adhesion molecule ICAM-1 resulting in reduced recruitment of CTLs
to ovarian cancer microenvironment. The negative impact of endothelin on
lymphocyte homing is sustained even in presence of pro-inflammatory cytokine
TNF-α. Hence, EDNRB activation in intratumoral endothelial cells creates an
endothelial

barrier

that

nourishes

immune-privileged

microenvironment.

Importantly, EDNRB blockage increased the expression of adhesion molecules
ICAM-1 in the vasculature followed by augmented homing of CTLs to TME
(Buckanovich et al., 2008). Overexpression of EDNRB in endothelial cells from
aggressive glioblastomas is associated with less CTL infiltrate and more Tregs
present in TME. This finding implicates that high expression of EDNRB in TME
impairs recruitment of tumor inhibitory immune cells while contributes to evasion
of immune detection (Nakashima et al., 2016). These data together with the
present study advocates for an immunosuppressive role of endothelin in TME
resulting in escape from tumor immunity.
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3.4.

Methods
Tumor cell injection

A total of 1,000,000 YUMMER1.7 melanoma cells (Wang et al., 2017) were
intradermally injected in the shaved flank of K5-Edn3 or wild-type mice as
described in 2.4.3. YUMMER1.7 cells were a gift from Dr. Marcus Bosenberg (Yale
University). The study was approved by the Institutional Animal Care and Use
Committee (IACUC) at Florida International University protocol number 16-018.
In vivo experiments
K5-Edn3 mice were intradermally injected with 100,000 YUMM1.7-GFP as
described in 2.4.3. When tumors became palpable (7 days after injection) mice
were randomized into 4 groups (n=3) to receive the treatments three times per
week for three weeks. Mice in the control group received intraperitoneal injection
of DMSO and isotype control Syrian Hamster IgG2 (Bio X Cell, BP0087). Mice in
the Ednrb inhibitor group were intraperitoneally treated with 10 mg/kg of BQ-788
(ApexBio, BP3278). Mice in the immunotherapy group were treated with 10 mg/kg
of anti-CTLA-4 (Bio X Cell, BP0131) clone 9H10 via intraperitoneal. Mice in the
combination group were simultaneous treated with BQ-788 and anti-CTLA-4.
Tumor volume was calculated as described in 2.4.3 and statistical analysis was
carried out with One-Way ANOVA and considered to be significantly different at
p<0.05.
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Real-time Quantitative PCR (qRT-PCR)
Total RNA from YUMM1.7-GFP tumors was extracted using Direct-Zol® RNA
MiniPrep Plus Kit (Zymo Research, R2070). Complementary DNA (cDNA)
synthesis was performed using RevertAid First Strand cDNA Synthesis Kit
(Thermo Scientific, K1622). Real-time quantitative PCR (qRT-PCR) was
conducted using Thermo Scientific Maxima SYBR Green Master Mix (Thermo
Scientific, K0221). Each sample was analyzed in triplicates and the relative mRNA
expression levels of FOXP3, TGF-β and IL-10 were normalized to those of
GAPDH.

Primers

sequences

CCCAGGAAAGACAGCAACCTT,
TGF-β:

forward

were
reverse

as

follows:

FOXP3:

forward

TTCTCACAACCAGGCCACTTG;

CCTGCAAGACCATCGACATG,

reverse

TGTTGTACAAAGCGAGCACC; IL-10: forward ATAACTGCACCCACTTCCCA,
reverse

GGGCATCACTTCTACCAGGT;

GAPDH:

forward

TGCAGTGGCAAAGTGGAGAT, reverse TTTGCCGTGAGTGGAGTCATA.
Western Blotting
Harvested YUMM1.7-GFP tumors were lysed using RIPA lysis buffer. Tissue
lysates were centrifuged at 16,000rpm at 4°C for 15min. The supernatant was
collected and denaturated using 4x NuPAGE LDS Sample Buffer with 5% βmercaptoethanol. Pre-cast 4-12% SDS-PAGE gels were used to analyze the
protein samples which were subsequently transferred to PVDF membrane. The
membranes were incubated with FOXP3 (1:1,000, Proteintech, 22228-1-AP) and
β-actin (1:4,000, Proteintech, 20536-1-AP) antibodies followed by HRP conjugated
secondary antibody (1:5,000, Cell Signaling Technology, 7074) incubation. Finally,
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the labeled proteins were visualized using chemiluminescence kit (Thermo
Scientific, 34577). Bands intensity were quantified using ImageJ software.
Statistical analysis was carried out with Student T-Test and considered to be
significantly different at p< 0.05.
Immunofluorescence Analysis
TGF-β (1:100, Abcam, ab92486) and GZB (1:100, Abcam, ab53097) primary
antibodies were used for immunofluorescence staining. The procedure was
performed as described in 2.4.5. GZB immunofluorescence staining was quantified
in terms of mean fluorescence intensity using ImageJ software. Twenty random
fields of four sections per tumor (n=4/group) were analyzed. Statistical analysis
was carried out with Student T-Test and considered to be significantly different at
p<0.05.
IL-10 ELISPOT
MultiScreen® 96-well plates (Millipore, MAIPS4510) were coated with mouse
IL-10 ELISPOT detection antibody (BD Biosciences, 51-9002752) and incubated
overnight at 4°C, washed three times with PBS and blocked with DMEM 10% FBS
for 2h at 37°C. Single-cells suspension from harvest YUMM1.7-GFP tumors were
prepared as described in 2.4.4. A total of 1,000,000 cells derived from tumor
dissociation were seeded in triplicates and incubated for 24h. After incubation wells
were washed three times with wash buffer (0.05% Tween-20 in PBS) and
incubated for 2h at room temperature with biotinylated mouse IL-10 ELISPOT
capture antibody (BD Biosciences, 51-9002772). Following incubation, wells were
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washed three times with wash buffer and incubated with avidin-HPR (Invitrogen,
18-4100-51) for 2h at room temperature. Spots were developed after incubation
with AEC Substrate Solution for 3min at room temperature. IL-10+ spots were
counted using CTL Immunospot S6 ELISPOT reader. Statistical analysis was
carried out with Student T-Test and considered to be significantly different at
p<0.05.
Cytokine array
Protein homogenates were prepared as described in 3.4.4. RayBiotech ®
Quantibody Mouse Cytokine Antibody Array (QAM-CAA-4000; RayBiotech) was
conducted by RayBiotech. This assay simultaneously detects and quantifies 200
cytokines and consisted of a multiplexed sandwich ELISA-based quantitative array
platform. The fluorescence intensity levels were normalized to internal positive
controls present in each array. Statistical analysis was carried out with Student TTest and proteins were considered differentially expressed when p<0.05.

141

3.5.

Figures

Figure 3.1 Immunosuppressive mechanisms of Treg in TME
Tregs have many immunosuppressive mechanisms that limit anti-tumor immunity in
TME. Tregs produce immunosuppressive cytokines TGF-β, IL-10 and IL-35 and uptake
available IL-2 through overexpression of CD25. Tregs also express granzyme B (GZB)
to directly kill CTLs and NK cells and prevent the co-stimulatory signaling in DCs through
expression of immune checkpoint CTLA-4.
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Figure 3.2 Endothelin is required for immune escape of YUMMER1.7 melanoma
cells
Tumor volume of mice (n=5) that received intradermal injections of YUMMER1.7
melanoma cells. **p<0.01
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Figure 3.3 Endothelin increases the expression of Tregs-associated markers in
the YUMM1.7-GFP melanoma tumors
qRT-PCR analysis of Foxp3, Tgf-β and Il-10 mRNA levels in wild-type and K5-Edn3
tumors. Fold change was calculated as the relative mRNA amount of target gene in
wild-type and K5-Edn3 tumors normalized to GAPDH. Shown is one of the three
experiments performed.
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Figure 3.4 Endothelin increases FOXP3 expression in YUMM1.7-GFP melanoma
tumors
A. Western blot analysis of FOXP3 and β-actin expression in intradermally injected
YUMM1.7-GFP tumors of wild-type and K5-Edn3 mice. B. Densitometric analysis of
FOXP3 expression relative to β-actin expression (n=3/group). *p<0.05.
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Figure 3.5 Endothelin increases TGF-β expression in YUMM1.7-GFP melanoma
tumors
Immunofluorescence staining of intradermally injected YUMM1.7-GFP tumors of wildtype (A) and K5-Edn3 (B) mice for TGF-β. TGF-β expression was observed only in K5Edn3 tumors.
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Figure 3.6 Endothelin increases IL-10 expression in YUMM1.7-GFP melanoma
tumors
A. Representative wells of IL-10 ELISPOT of intradermal YUMM1.7-GFP tumors of wildtype and K5-Edn3 mice. B. Quantification of IL-10+ cells. **p<0.01. Shown is one of the
two experiments performed.
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Figure 3.7 Endothelin increases granzyme B (GZB) expression in YUMM1.7-GFP
melanoma tumors
A. Immunofluorescence staining in YUMM1.7-GFP intradermal tumors of wild-type (left)
and K5-Edn3 (center) mice for Granzyme. B. Mean fluorescence intensity analysis of
20 random fields per tumor (n=4/group). **p<0.01.
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Figure 3.8 Endothelin increases the number of Ednrb+ Tregs relative to cytotoxic
cells in YUMM1.7-GFP melanoma tumors
Flow cytometric quantification of Treg Ednrb+ relative to CTLs cells from intradermal
YUMM1.7-GFP tumors of wild-type and K5-Edn3 mice (n=3/group). *p<0.05.
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Figure 3.9 Immune checkpoint and Ednrb inhibitor decreased melanoma growth
K5-Edn3 mice bearing YUMM1.7-GFP tumors were treated with BQ-788 (10 mg/Kg)
alone, anti-CTLA-4 (10 mg/Kg) alone or in combination three times a week for three
weeks. A. Tumor volume of K5-Edn3 mice that received drug treatments (n=3). B.
Representative tumor of each group after resection. *p<0.05, ***p<0.0001
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Figure 3.10 Endothelin suppress the expression of inflammatory proteins in
YUMM1.7-GFP melanoma tumors
Changes in protein expression of the YUMM1.7-GFP tumors of wild-type and K5-Edn3
were analyzed by RayBiotech Quantibody® Mouse Cytokine Array. The fluorescence
intensity levels were normalized to internal positive controls present in each array.
Normalized fluorescence intensity for 15 differentially expressed proteins (p<0.05) are
represented in the heat map (A) and as the mean +/-S.E.M. (B) (n=3/group). *p<0.05,
**p<0.01.
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4.1.

Conclusions and Implications

Melanoma is the deadliest type of skin cancer accounting for 75% of all deaths
related to cutaneous tumors (Schadendorf et al., 2015). The high mortality rate
associated with melanoma is due to its remarkable metastatic potential (Damsky,
Theodosakis and Bosenberg, 2014). Many cytokines are associated with
melanoma progression, among them are the endothelins. Endothelins are
cytokines ubiquitously expressed in the microenvironment of several tumors
(Nelson et al., 2003). In carcinomas and glioblastoma the components of
endothelin signaling are expressed by different cell types within TME (Aubert and
Juillerat-Jeanneret, 2016). In melanoma is not clear whether stromal cells respond
to the endothelin present in the microenvironment.
The present study corroborated previous findings (Demunter et al., 2001; Tang
et al., 2008) demonstrating that Edn3/Ednrb signaling activation in melanoma
increases tumor aggressiveness. In this study I showed that activation of
endothelin signaling mediated aggressiveness of a broad range of melanomas,
including BRAFV600E and BRAF wild-type melanomas. Few melanoma cells
expressed Ednrb in the YUMM1.7-GFP melanoma microenvironment suggesting
an environmental role for endothelin signaling in melanoma microenvironment.
The present study showed for the first time that Ednrb is expressed in several cell
populations inside melanoma microenvironment. The clinical relevance of this
finding was validated using publicly available RNA-seq data from melanoma
patients (Tirosh et al., 2016). To a certain extent, Ednrb was expressed in both
pro- and anti-tumorigenic cells indicating that endothelin activation might have
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multiple effects in melanoma microenvironment. Since K5-Edn3 tumors exhibited
a more aggressive phenotype it is possible that in Edn3-rich microenvironment the
net result benefited pro-tumorigenic cells. To date, no other study has shown
Ednrb expression in intratumoral Tregs. Treg was the only population that was
numerically different when K5-Edn3 tumors were compared to wild-type tumors.
This data suggests that when Edn3 is present in melanoma microenvironment
there is an enrichment of intratumoral Tregs. Tumor-infiltrating Tregs suppress
anti-tumor immunity (Nishikawa and Sakaguchi, 2010). Therefore, it is reasonable
to claim that in abundance of Edn3 Tregs create an immunosuppressive
environment in melanoma tumors granting escape from immunosurveillance.
Melanoma is recognized as one of the most immunogenic types of tumors
(Passarelli et al., 2017). Melanoma also develops an immunosuppressive
microenvironment resulting in evasion from immune detection and ultimately
metastasis formation (Umansky and Sevko, 2012). Endothelins are commonly
considered pro-inflammatory cytokines given their stimulatory roles during
inflammatory response (Nett et al., 2006). Over the past years, mounting data have
challenged the paradigm that endothelin solely stimulates inflammatory response.
The present study supports the notion that endothelin promotes the formation of
an immunosuppressive milieu in melanoma facilitating escape from tumor
immunity. Endothelin was required for immune escape of highly immunogenic
melanoma cells YUMMER1.7. Tregs orchestrated immunosuppression in
YUMM1.7-GFP melanoma tumors. FOXP3 is considered the master regulator of
Tregs suppressive functions (Fontenot, Gavin and Rudensky, 2003; Hori, Nomura
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and Sakaguchi, 2003). FOXP3 was remarkably upregulated in K5-Edn3 tumors
confirming that Edn3 overexpression in melanoma microenvironment is associated
with Treg enrichment. Tregs disrupt immune response against tumor through the
secretion of immunosuppressive cytokines TGF-β and IL-10 (Yi et al., 2013).
Accordingly, K5-Edn3 tumors exhibited high levels of TGF-β and IL-10. This
observation suggested that in presence of Edn3, the immunosuppressive features
of Tregs are enhanced. Indeed, activation of endothelin signaling in Tregs
prevented the expansion of CTLs possibly via GZB-mediated cytolysis. These data
indicated that the response of Tregs to endothelin impaired immune response
against melanoma. Unexpectedly, expression of chemokines and inflammatory
cytokines were downregulated in K5-Edn3 tumors. Cytokines that elicit anti-tumor
immunity, namely IL-17E and IL-28 (Numasaki et al., 2007; Zou and Restifo, 2010),
exhibited reduced levels in K5-Edn3 tumors. This result endorsed the idea that
endothelin mitigated tumor immunity in YUMM1.7-GFP melanoma tumors.
Importantly, this is the first report to associate overexpression of endothelin with
reduction of IL-28 production. YUMM1.7-GFP tumors exposed to high levels of
Edn3 were sensitive to immune checkpoint inhibitor (anti-CTLA-4) as well as to
Ednrb blockage (BQ-788), although the response to BQ-788 was more
pronounced.
Metastatic melanoma has a very poor prognosis with the 1-year overall survival
rate around 25% (Korn et al., 2008). Although YUMM1.7-GFP tumors responded
to high levels of Edn3 by growing larger, few metastatic lesions were observed,
and only in K5-Edn3 mice. YUMM1.7 cells mirror the genetic alterations commonly
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found in human melanomas, namely BRafV600E/+;Pten-/-; Cdkn2a-/- mutations, but
were shown to have limited metastatic features (Meeth et al., 2016). Therefore, the
findings from the present study should be viewed with caution regarding melanoma
metastasis.
The anti-metastatic potential of immune checkpoint and Ednrb inhibitors was
not assessed in the current study. Still, YUMM1.7-GFP tumors exposed to high
levels of Edn3 were sensitive to immune checkpoint inhibitor and Ednrb blockage
as both treatments significantly decreased tumor growth. Increased tumor volume
is correlated with elevated likelihood of melanoma dissemination to distant organs
(Walton et al., 2015). Thus, it is plausible that, in the context of Edn3
overexpression, immune checkpoint inhibitor as well as Ednrb blockage may have
prevented melanoma metastasis formation.
Altogether the data in the present study advocate for an environmental role of
Edn3/Ednrb signaling in melanoma. Endothelin mediates immunosuppression in
melanoma microenvironment resulting in escape from tumor immunity. These
findings are summarized in Figure 4.1. The present study endorses the framework
that endothelin signaling may have multiple effects in the melanoma
microenvironment given that melanoma cells and different populations of stromal
cells expressed Ednrb in the YUMM1.7-GFP tumors. Melanoma cells may be
directly affected by an Edn3-rich microenvironment. It has already been shown that
melanoma cells express EDNRB (Asundi et al., 2011; Bagnato et al., 2004b;
Lahav, Heffner, & Patterson, 1999; Yohn et al., 1994). Activation of EDNRB on
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melanoma cells triggers many cellular events relevant for tumor progression such
as proliferation, migration, and invasion of melanoma cells (Bagnato et al., 2004a).
Endothelins are also secreted by melanoma cells (Chiriboga et al., 2016; Tang et
al., 2008). In the context of Edn3 overexpression, it is possible that the autocrine
activation of Ednrb in melanoma cells enhanced the abovementioned cellular
events.
Abundance of Edn3 in the melanoma microenvironment might also have
indirectly favored melanoma cells. Activation of endothelin signaling in fibroblasts
induces secretion of ECM components and metalloproteinases (Knowles et al.,
2012), which might have created a permissive stroma for melanoma cell growth
and invasion. Endothelin signaling controls angiogenic events in endothelial cells
(Salani, Taraboletti, et al., 2000). New blood vessels increase nutrient supply to
tumor cells as wells as create new routes for metastatic cell dispersion (Smith and
Kang, 2013). YUMM1.7-GFP melanomas from both wild-type and K5-Edn3 mice
exhibited anti- and pro-tumorigenic immune cells expressing Ednrb, which
indicates potential opposite functions of endothelin signaling in the melanoma
microenvironment. Given that K5-Edn3 tumors have a more aggressive
phenotype, it is reasonable to suggest that an Edn3-rich microenvironment favors
the effect of endothelin in pro-tumorigenic cells. The present study explored the
suppressive role of Edn3 in the melanoma microenvironment. The context of
impaired tumor immunity seems to benefit melanoma cells given that anti-tumor
cells might become unable to recognize and kill cancer cells.
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4.2.

Future Directions

The present study proposes that melanoma should be added to the roster of
tumor types in which activation of endothelin signaling has a microenvironmental
role. Ultra-violet light (UV) exposure is considered the major risk factor for
melanoma (Lawrence et al., 2013). Interestingly, keratinocytes release endothelin
upon UV light exposure (Imokawas, Yada and Miyagishi, 1992). In the K5-Edn3
mouse model (Garcia et al., 2008) overexpression of Edn3 is restricted to
keratinocytes. Thus, K5-Edn3 mice used in this study constitute a suitable system
to explore the microenvironmental role of endothelin in melanoma. A different
approach to validate the observations made using the K5-Edn3 mouse model
would be the injection of melanoma cells in mice that lack expression of Ednrb.
The piebald lethal (Ednrbsl sl) mouse would be appropriate for further studies since
it harbors spontaneous deletion in the Ednrb gene (Hosoda et al., 1994). Injection
of YUMM1.7-GFP melanoma cells in piebald lethal mice would corroborate the
microenvironmental role Edn3/Ednrb signaling in melanoma microenvironment. A
similar strategy was employed to describe the stromal functions of Ednrb in breast
cancer. Injection of breast cancer cells overexpressing Ednra generated tumors
with diminished growth and metastatic potential in Ednrb deficient rat. Absence of
stromal Ednrb impaired immune cells infiltration and cytokine production resulting
in reduced tumor aggressiveness. Lack of Ednrb in TME decreased the
recruitment of TAMs and the amount of pro-inflammatory cytokine TNF-α (Binder
et al., 2009).
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The present study suggested that endothelin promotes evasion from tumor
immunity in YUMMER1.7 melanomas. It has been demonstrated that Tregs
prevents the regression of YUMMER1.7 tumors (Wang et al., 2017). It was not
clear

whether

activation

of

Ednrb

in

Tregs

mediated

the

impaired

immunosurveillance in YUMMER1.7 tumors from K5-Edn3 mice. Flow cytometry
experiments using Ednrb and CD25 antibodies should be performed in K5-Edn3
tumors to test if activation of endothelin signaling in Tregs plays a role during
YUMMER1.7 immune escape. Additionally, FOXP3 expression at mRNA and
proteic level should be carried out in K5-Edn3 tumors to confirm that endothelin is
required for Treg suppressive functions in YUMMER1.7 melanomas.
The current data implicated that overexpression of Edn3 in melanoma
microenvironment results in intratumoral Tregs enrichment. Still, the mechanism
responsible for Tregs accumulation in K5-Edn3 tumors was not explored. It is
possible that endothelin impacted Tregs proliferation, recruitment or conversion of
conventional T cells into Tregs (Lee, 2017). In order to clarify the role of Ednrb
activation in Tregs, suppressive cells should be isolated from tumors using Treg
isolation kit (MACS Miltenyi Biotec, 130-091-041) and treated with Edn3. Treg
proliferation can be addressed using CFSE dilution. The migratory effect of Tregs
in response to endothelin could be assessed using Boyden chamber assay. To
test if endothelin mediates the conversion of conventional T cells into Tregs
isolated naïve CD4+ T cell should be cultivated in presence of Edn3. It is possible
that isolation of intratumoral Tregs using Treg isolation kit yield a small number of
cells. Alternatively, mouse spleen can be use as Treg source.
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Production of GZB by intratumoral Tregs suppresses the anti-tumor response
of NKs and CTLs (Cao et al., 2007). Nevertheless, GZB is also expressed by CTLs
and NKs (Lieberman, 2003). Due to technical limitations, it was not possible to
demonstrate that Tregs accounted for augmented expression of GZB in K5-Edn3
tumors. In order to elucidate whether activation of endothelin signaling triggers
GZB expression in Tregs, isolated Tregs should be cultured in presence of Edn3
and GZB expression measured using qRT-PCR and Western Blotting.
Preclinical studies have shown that Ednrb inhibition effectively reduced
melanoma growth (Lahav, Heffner and Patterson, 1999; Spinella et al., 2007;
Smith et al., 2017). The clinical relevance of EDNRB blockage is still elusive
(Kefford et al., 2007; Wouters et al., 2015). This is probably due to the lack of
previous screening for patients with high levels of EDNRB. Immunotherapy
approaches using immune checkpoint inhibitors have reached exciting results in
patients with melanoma. Yet, some patients do not respond to immunotherapies
and new strategies are imperatively required (Binnewies et al., 2018). The data
from the present study indicate that Ednrb blockage might improve the outcome of
immunotherapies.

Indeed,

EDNRB

blockage

enhanced

the

results

of

immunotherapy in a preclinical study of ovarian cancer (Buckanovich et al., 2008).
Additional studies using large cohorts should be carried out to validate the
successful preliminary results of Ednrb inhibitor treatment in K5-Edn3 mice bearing
YUMM1.7-GFP melanomas. Further, clinical trials aiming to block endothelin
signaling might be performed in melanoma patients that express high levels of
EDNRB and are under ipilimumab treatment.
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4.3.

Figure

Figure 4.1 Microenvironmental role of Edn3/Ednrb signaling in melanoma
Several cell types are present in the microenvironment of melanomas that express
endogenous levels of Edn3. In these tumors there is reduced expression on
immunosuppressive cytokines IL-10 and TGF-β as well as GZB. Chemokines and
cytokines that elicit anti-tumor immunity are highly expressed in melanomas that exhibit
endogenous levels of End3. Conversely, melanomas growing in Edn3-rich
microenvironment exhibit enrichment of Ednrb+ Tregs. Endothelin promotes the
formation of an immunosuppressive milieu characterized by augmented expression of
immunosuppressive cytokines IL-10 and TGF-β as well as GZB and diminished levels
of inflammatory cytokines and chemokines.
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